[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3480
1. Gumy-Pause F, Wacker P, Maillet P, Betts DR, Sappino AP: ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2006 Mar;20(3):526-7; author reply 527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leukemia. 2005 Nov;19(11):1887-95 [16167060.001]
  • (PMID = 16408093.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


2. Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJ, Cloos J: Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res; 2008 Jan;32(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
  • We studied these polymorphisms in children with acute lymphoblastic leukaemia (ALL) and in subjects without malignancy in Indonesia and Holland.
  • [MeSH-major] Genetic Predisposition to Disease. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Thymidylate Synthase / genetics

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395259.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.45 / Thymidylate Synthase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. McClintock-Treep SA, Horny HP, Sotlar K, Foucar MK, Reichard KK: KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation. J Clin Pathol; 2009 Dec;62(12):1147-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
  • A case of systemic mastocytosis associated with a clonal haematological non-mast cell lineage disease (SM-AHNMD), where the associated disease is acute erythroid leukaemia (erythroid/myeloid type), is reported.
  • Interestingly, molecular studies showed the KIT(D816V+) mutation not only in the mast cells, but also in the myeloid blast population and the leukaemic erythroid cells.
  • As is the case with most erythroid leukaemias, the patient had a very aggressive clinical course and died shortly after diagnosis.
  • It is believed that this is the first reported case of systemic mastocytosis with erythroid leukaemia where the KIT(D816V+) mutation was detected in all three cell types.
  • Molecular findings provide evidence for derivation of these seemingly morphologically distinct lesions from the same clonal precursor cell.
  • From a practice standpoint, this case illustrates the importance of definitively diagnosing the associated non-mast cell lineage disease due to its prognostic implications.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / genetics. Mastocytosis, Systemic / genetics. Mutation. Proto-Oncogene Proteins c-kit / genetics

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729359.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


Advertisement
4. Willemze AJ, Geskus RB, Noordijk EM, Kal HB, Egeler RM, Vossen JM: HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant; 2007 Aug;40(4):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical haematopoietic stem cell transplantation for acute leukaemia in children: less relapse with higher biologically effective dose of TBI.
  • To examine relapse, survival and transplant-related complications in relationship to disease- and pre-treatment-related characteristics, we evaluated 132 children, who consecutively received an allogeneic HLA-identical SCT for acute leukaemia in our centre: ALL in first remission (n=24), ALL in second remission (n=53) and AML in first remission (n=55).
  • The incidence of acute GVHD was 17%; 6% was grades II-IV.
  • AML patients with acute GVHD got no relapse (P=0.02); this was not the case in ALL patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / methods
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Graft Survival. Graft vs Host Disease. Humans. Infant. Kaplan-Meier Estimate. Male. Recurrence. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572715.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Shaw BE, Russell NH: Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant; 2008 Mar;41(5):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
  • The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 91
  •  go-up   go-down


6. Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W: Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol; 2007;14(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
  • In this work, reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the gene expression (mRNA) of CD30 variant (CD30v) and CD30 Ligand (CD30L) on the peripheral blood mononuclear cells (PBMCs) of 15 healthy individuals as a control group, 15 patients with newly diagnosed acute myeloid leukemia (AML) and 15 patients with newly diagnosed acute lymphocytic leukemia (ALL).
  • Patients with positive expression of CD30v and CD30L were found to have significantly increased blast cell % (p<0.001), increased total leucocytic count (P<0.001) and decreased platelets count (P<0.001) than those with negative expression.
  • As regard to immunophenotypes of ALL, positive expression was found to be significantly higher in B-cell than T-cell subtype (77.8% versus 16.7%, P=0.02).
  • Positive expression was also significantly associated with more aggressive disease and with B-cell than T-cell subtypes.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689277.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / RNA, Messenger
  •  go-up   go-down


7. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S: Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Bone Marrow Transplant; 2005 Oct;36(7):565-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
  • Reduced-intensity stem cell transplantation (RIST) has been shown to be a safe and useful alternative transplant method for patients including elderly and medically unfit patients.
  • RIST conditioning regimens vary widely in the intensity of myeloablation, immunoablation, and antileukemia effects, and thus optimal regimen for each disease entity is yet to be determined.
  • In acute myeloid leukemia (AML), moderate-intensity regimens may be effective, achieving 30-70% 1-year disease-free survival in various series, but minimal-intensity regimens are associated with high relapse rates.
  • In acute lymphoblastic leukemia (ALL), not even moderate-intensity regimens are effective and most patients with advanced ALL relapse post transplant.
  • Thus, the risk/benefit ratios of graft-versus-host disease/graft-versus-leukemia effect differ among diseases.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease-Free Survival. Graft vs Host Disease. Humans. Middle Aged. Multicenter Studies as Topic. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995714.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


8. Kiefel V, Greinacher A: [Differential diagnosis and treatment of thrombocytopenia]. Internist (Berl); 2010 Nov;51(11):1397-410
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment of thrombocytopenia].
  • Important differential diagnoses in patients with severe thrombocytopenia are: acute leukemia, thrombotic thrombocytopenic purpura, autoimmune thrombocytopenia and drug-dependent thrombocytopenia.
  • Treatment should focus on the underlying disease.
  • [MeSH-major] Thrombocytopenia / diagnosis. Thrombocytopenia / etiology
  • [MeSH-minor] Chromosomes, Human, Pair 22 / genetics. DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Molecular Motor Proteins / genetics. Myosin Heavy Chains / genetics. Platelet Count. Pregnancy. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Onkologie. 2010;33 Suppl 3:2-20 [20484949.001]
  • [Cites] Hamostaseologie. 2006 Jan;26(1):72-4; quiz 75-8 [16444327.001]
  • [Cites] Ann Intern Med. 2001 Oct 16;135(8 Pt 1):589-93 [11601930.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1158-64 [17768118.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Apr;28(4):619-24 [15100613.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):169-81 [3317856.001]
  • [Cites] Curr Opin Hematol. 2008 Sep;15(5):445-50 [18695366.001]
  • [Cites] Haematologica. 2003 May;88(5):582-92 [12745278.001]
  • [Cites] Semin Thromb Hemost. 2009 Mar;35(2):189-203 [19408192.001]
  • [Cites] Int J Hematol. 2005 Feb;81(2):119-25 [15765779.001]
  • [Cites] Hamostaseologie. 2010 Jan;30(1):17-8, 20-8 [20162249.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:153-8 [20008194.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1560-4 [8177245.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6288-95 [19351959.001]
  • (PMID = 20941473.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MYH9 protein, human; 0 / Molecular Motor Proteins; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


9. Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS: Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr; 2006 May;148(5):687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
  • Transient myeloproliferative disorder (TMD) occurs in 10% of infants with Down syndrome (DS).
  • Down syndrome infants with resolved TMD may later develop acute megakaryocytic leukemia (AMKL).
  • We report on a non-DS child identified with trisomy 21 mosaicism and a GATA1 mutation in the original blast cells who has been followed for 2 years without exhibiting AMKL.
  • Currently, the risk for such infants developing acute leukemia is uncertain.
  • [MeSH-major] GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Myeloproliferative Disorders / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2007 Mar;150(3):e34 [17307526.001]
  • (PMID = 16737888.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor
  •  go-up   go-down


10. Haddy N, Le Deley MC, Samand A, Diallo I, Guérin S, Guibout C, Oberlin O, Hawkins M, Zucker JM, de Vathaire F: Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood. Eur J Cancer; 2006 Nov;42(16):2757-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood.
  • The aim of this study was to determine the therapy-related risk factors for the occurrence of leukaemia after childhood solid cancer.
  • Among 4204 3-year survivors of a childhood cancer treated in eight French and British centres before 1986, 11 patients developed leukaemia as a second malignant neoplasm (SMN).
  • Compared with the leukaemia incidence in the general French and British populations, the standardised incidence ratio (SIR) of leukaemia was 7.8 (95% CI 4.0-13.4).
  • Radiotherapy appeared to increase the risk of leukaemia at moderate weighted doses to active bone marrow; the relative risk (RR) was 4.2 (95% CI 0.8-20.7) for doses ranging from 3 to 6.6 Gy.
  • No specific type of first malignant neoplasm (FMN) was found to lead to a higher risk of secondary leukaemia.
  • Epipodophyllotoxins and vinca alkaloids at high doses and moderate weighted radiation doses to active bone marrow may contribute independently to an increased risk of leukaemia for patients treated for childhood cancer.
  • Our results suggest that the long-term risk of secondary leukaemia could be higher than previously reported.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Epidemiologic Methods. France / epidemiology. Great Britain / epidemiology. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965909.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Chabrol A, Cuzin L, Huguet F, Alvarez M, Verdeil X, Linas MD, Cassaing S, Giron J, Tetu L, Attal M, Récher C: Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica; 2010 Jun;95(6):996-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.
  • BACKGROUND: Invasive aspergillosis is a common life-threatening infection in patients with acute leukemia.
  • This study assessed the impact of voriconazole or caspofungin prophylaxis in patients undergoing induction chemotherapy for acute leukemia in a hematology unit exposed to building work.
  • The diagnosis of invasive aspergillosis was based on the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria.
  • RESULTS: Two-hundred and fifty-seven patients (213 with acute myeloid leukemia, 44 with acute lymphocytic leukemia) were included.
  • Invasive aspergillosis was diagnosed in 21 patients (12%) in the non-prophylaxis group and four (4.5%) in the prophylaxis group (P=0.04).
  • Pulmonary antecedents, neutropenia at diagnosis and acute myeloid leukemia with high-risk cytogenetics were positively correlated with invasive aspergillosis, whereas primary prophylaxis was negatively correlated.
  • CONCLUSIONS: This study suggests that antifungal prophylaxis with voriconazole could be useful in acute leukemia patients undergoing first remission-induction chemotherapy in settings in which there is a high-risk of invasive aspergillosis.
  • [MeSH-major] Air Pollutants / adverse effects. Construction Materials / adverse effects. Echinocandins / administration & dosage. Invasive Pulmonary Aspergillosis / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Triazoles / administration & dosage

  • Genetic Alliance. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [Cites] Am J Hematol. 2001 Apr;66(4):257-62 [11279636.001]
  • [Cites] J Hosp Infect. 2001 Jul;48(3):198-206 [11439007.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:54-61 [11525219.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):288-96 [12183144.001]
  • [Cites] Infect Control Hosp Epidemiol. 1990 May;11(5):235-42 [2351809.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1752-7 [10325319.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Leukemia. 2006 Mar;20(3):400-3 [16437142.001]
  • [Cites] J Hosp Infect. 2006 Jul;63(3):246-54 [16713019.001]
  • [Cites] Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12 [16626917.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):738-44 [16842568.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):348-59 [17251531.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1289-97 [17443465.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1025-8 [17426258.001]
  • [Cites] J Infect. 2007 Nov;55(5):445-9 [17822770.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1327-34 [18024370.001]
  • [Cites] Clin Infect Dis. 2008 Jun 15;46(12):1813-21 [18462102.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):358-66 [11170942.001]
  • (PMID = 20007135.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC2878800
  •  go-up   go-down


12. Zalewska-Szewczyk B, Matusiak I, Wyka K, Trelińska J, Stolarska M, Młynarski W: [Changes in the lipid profile in children with acute lymphoblastic leukaemia - the influence of the disease and its treatment]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1035-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in the lipid profile in children with acute lymphoblastic leukaemia - the influence of the disease and its treatment].
  • The aim of the study was a prospective evaluation of the lipid profile in children with acute lymphoblastic leukaemia, before and during the treatment with L-asparaginase.
  • At the moment of diagnosis significantly low concentration of total cholesterol (124 mg/dl (103-153) vs 161 mg/dl (143-185), p=0,011) and HDL cholesterol (23 mg/dl (17-27) vs 56 mg/dl (44-64), p=0,00001) were observed, as well as high concentration of triglycerides (112 mg/dl (83-162) vs 73 mg/dl (62-99), p=0,009).
  • CONCLUSIONS: At the moment of diagnosis of ALL the potentially atherogenic lipid profile could be established.
  • [MeSH-major] Asparaginase / therapeutic use. Lipid Metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531822.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


13. El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF: Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Canc Inst; 2006 Sep;18(3):244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia.
  • BACKGROUND: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered particularly useful for identifying aberrant lineage association of acute leukemia, biphenotypic and bilineal acute leukemia, as well as monitoring minimal residual disease.
  • THE AIM OF OUR STUDY: Is to determine aberrant lymphoid antigen expression in Saudi acute myeloid leukemia (AML), correlate them with FAB subtypes, evaluate early surface markers CD7 and CD56, and to investigate the role of cytoplasmic CD79a (a B cell marker that is assigned a high score of 2.0 in the WHO classification).
  • CD79a was expressed in one case together with CD19, diagnosed as acute biphenotypic leukemia, and was associated with t(8;21) (q22;q22).
  • CONCLUSION: Minimal residual disease in AML is very difficult to trace, detection of aberrant expression of lymphoid antigens will make it easier.
  • [MeSH-major] Antigens, CD56 / analysis. Antigens, CD7 / analysis. Antigens, CD79 / analysis. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / diagnosis


14. Spanevello M, Morris KL, Kennedy GA: Pseudoaneurysm formation by Scedosporium prolificans infection in acute leukaemia. Intern Med J; 2010 Nov;40(11):793
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoaneurysm formation by Scedosporium prolificans infection in acute leukaemia.
  • [MeSH-major] Aneurysm, False / diagnosis. Leukemia / diagnosis. Mycetoma / diagnosis. Scedosporium / isolation & purification
  • [MeSH-minor] Acute Disease. Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155161.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Slevin M, Krupinski J, Mitsios N, Perikleous C, Cuadrado E, Montaner J, Sanfeliu C, Luque A, Kumar S, Kumar P, Gaffney J: Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke. Eur J Neurol; 2008 Jan;15(1):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia inhibitory factor is over-expressed by ischaemic brain tissue concomitant with reduced plasma expression following acute stroke.
  • Leukaemia inhibitory factor (LIF) is a glycoprotein of the interleukin-6 family, which has potent pro-inflammatory properties and is involved in regulation of neuronal differentiation.
  • We have previously identified its upregulation in gene microarrays following acute ischaemic stroke in man.
  • LIF expression and localization was measured in human ischaemic stroke autopsy specimens, in a rat model of middle cerebral artery occlusion (MCAO) and in human foetal neural cell cultures following oxygen-glucose deprivation (OGD) by Western blotting and immunohistochemistry.
  • Circulating LIF was determined in the plasma of patients in the hyper-acute stroke phase using a multiplex enzyme-linked-immunosorbent serologic assay system.
  • Circulating serum LIF expression was significantly decreased in the hyper-acute phase of stroke.
  • Increased LIF expression in peri-infarcted regions and sequestration from the peripheral circulation in acute stroke patients are characteristic of the pathobiological response to ischaemia and tissue damage.
  • [MeSH-major] Brain / metabolism. Brain Ischemia / blood. Brain Ischemia / physiopathology. Leukemia Inhibitory Factor / blood. Stroke / blood. Stroke / physiopathology
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Animals. Cells, Cultured. Coculture Techniques. Disease Models, Animal. Disease Progression. Endothelial Cells. Female. Humans. Infarction, Middle Cerebral Artery / blood. Infarction, Middle Cerebral Artery / physiopathology. Male. Middle Aged. Neuroglia / metabolism. Neurons / metabolism. Rats. Rats, Sprague-Dawley. Up-Regulation / physiology


16. Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K: R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer; 2007 Nov 19;97(10):1344-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • R306465 potently inhibited cell proliferation of all main solid tumour indications, including ovarian, lung, colon, breast and prostate cancer cell lines, with IC50 values ranging from 30 to 300 nM.
  • Haematological cell lines, including acute lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphoblastic leukaemia, chronic myeloid leukaemia, lymphoma and myeloma, were potently inhibited at a similar concentration range.
  • R306465 induced apoptosis and inhibited angiogenesis in cell-based assays and had potent oral in vivo antitumoral activity in xenograft models.
  • The high activity of R306465 in cell-based assays and in vivo after oral administration makes R306465 a promising novel antitumoral agent with potential applicability in a broad spectrum of human malignancies.
  • [MeSH-minor] Administration, Oral. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / chemistry. Angiogenesis Inhibitors / pharmacology. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Disease Models, Animal. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Histones / drug effects. Histones / metabolism. Humans. Immunohistochemistry. Isoenzymes / antagonists & inhibitors. Male. Mice. Mice, Nude. Promoter Regions, Genetic / drug effects. Promoter Regions, Genetic / genetics. Rats. Rats, Sprague-Dawley. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Mar 31;160(7):1017-27 [12668657.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] Nat Med. 2001 Apr;7(4):437-43 [11283670.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):45-57 [11804585.001]
  • [Cites] Nature. 2002 May 23;417(6887):455-8 [12024216.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2672-81 [12032080.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):287-99 [12120280.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):937-41 [12481415.001]
  • [Cites] EMBO J. 2002 Dec 16;21(24):6820-31 [12486003.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):607-19 [12509458.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1168-79 [12606581.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2669-79 [12665570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4389-94 [12677000.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):401-8 [12700284.001]
  • [Cites] Chem Biol. 2003 May;10(5):397-410 [12770822.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):353-8 [14506733.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):529-36 [14521942.001]
  • [Cites] Curr Med Chem. 2003 Nov;10(22):2343-50 [14529477.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):720-8 [12975486.001]
  • [Cites] Cell. 2003 Dec 12;115(6):727-38 [14675537.001]
  • [Cites] Prostate. 2004 May 1;59(2):177-89 [15042618.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5271-81 [15297431.001]
  • [Cites] J Med Chem. 2004 Oct 7;47(21):5235-43 [15456267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15064-9 [15477595.001]
  • [Cites] Cytometry. 1983 Mar;3(5):332-9 [6188587.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):115-22 [1695694.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Lab Invest. 1995 Nov;73(5):734-9 [7474948.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):683-90 [15541343.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:495-528 [15822187.001]
  • [Cites] FASEB J. 2005 Jun;19(8):966-8 [15772115.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] J Cell Biochem. 2005 Oct 1;96(2):293-304 [16088937.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(14):5259-69 [16809764.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6785-92 [16818655.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2317-23 [16985066.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • (PMID = 18000499.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Hydroxamic Acids; 0 / Isoenzymes; 0 / R 306465; 0 / Sulfones
  • [Other-IDs] NLM/ PMC2360244
  •  go-up   go-down


17. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


18. Torres T JP, Concha V E, López G JP, Cofre G J: [Acute retinal necrosis in an acute leukemia pediatric patient]. Rev Chilena Infectol; 2007 Aug;24(4):323-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute retinal necrosis in an acute leukemia pediatric patient].
  • [Transliterated title] Necrosis retinal aguda en un paciente pediátrico con leucemia aguda.
  • Acute retinal necrosis (ARN) is a serious condition that can impair vision.
  • It mostly occurs in adult patients, especially those severely immunocompromised, in association with a reactivation of a herpes virus infection.
  • We present a 4 years old patient with high risk acute leukemia, whom during a course of intense chemotherapy acquired chickenpox with visceral involvement that affected the retina, causing unilateral blindness.
  • [MeSH-major] Chickenpox / complications. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Necrosis Syndrome, Acute / virology

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728923.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


19. Chandrasekar P: Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation. Med Mycol; 2009;47 Suppl 1:S349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
  • Availability of newer, well tolerated anti-Aspergillus drugs at a time of rising prevalence of invasive aspergillosis has sparked enthusiasm for chemoprophylaxis against Aspergillus in allogeneic stem cell recipients.
  • Posaconazole, approved for prophylaxis in allogeneic stem cell recipients with graft versus host disease and in those with acute leukemia, is of promise but has a limitation relating to its oral bioavailability.
  • [MeSH-major] Aspergillosis / prevention & control. Chemoprevention / methods. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663660.001).
  • [ISSN] 1460-2709
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 33
  •  go-up   go-down


20. Apostolidou E, Swords R, Alvarado Y, Giles FJ: Treatment of acute lymphoblastic leukaemia : a new era. Drugs; 2007;67(15):2153-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukaemia : a new era.
  • Acute lymphocytic leukaemia (ALL) is a heterogeneous group of disorders that result from the clonal proliferation and expansion of malignant lymphoid cells in the bone marrow, blood and other organs.
  • However, only approximate, approximately 30-40% of adults achieve long-term disease-free survival.
  • The optimal treatment of Philadelphia chromosome-positive patients requires the addition of BCR-ABL tyrosine kinase inhibitors, such as imatinib, whereas allogeneic stem-cell transplantation remains the preferred approach for high-risk patients in first remission.
  • Since only approximate, approximately 38% of adult ALL patients are free of disease 5 years after diagnosis and the outcome of salvage chemotherapy is very poor (complete remission rates of 20-30%, median survival of 3-6 months), novel agents are desperately required.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Chemistry, Pharmaceutical. Folic Acid Antagonists / therapeutic use. Humans. Microtubules / drug effects. Nucleosides / therapeutic use. Oncogene Proteins v-abl / antagonists & inhibitors. Proto-Oncogene Proteins c-bcr / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;46(5):427-32 [11127949.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Semin Oncol. 2005 Apr;32(2 Suppl 2):S5-8 [15818537.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1765-9 [16721371.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):521-31 [9118464.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8 [16467096.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Summer;8(2):99-104 [3526939.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:147-50 [8481663.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2549-55 [17041099.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2814-22 [1835410.001]
  • [Cites] Blood. 2007 Apr 1;109 (7):2744-50 [17132721.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6615-24 [16166440.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):69-72 [10690390.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1464-8 [15054472.001]
  • [Cites] Curr Med Chem. 1999 Apr;6(4):329-52 [10101216.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):127-34 [9654112.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Jun;6(6):623-30 [15988914.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1641-2 [2145440.001]
  • [Cites] Clin Transl Oncol. 2006 Aug;8(8):560-5 [16952844.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):37-48 [8457713.001]
  • [Cites] Rev Pneumol Clin. 2005 Sep;61(4 Pt 2):4S5-7 [16273001.001]
  • [Cites] Pharmacol Ther. 1991 Oct;52(1):35-84 [1687171.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):401-12 [15923057.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Dec;43(12):567-9 [16372519.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10 (16):5335-41 [15328169.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Cancer Res. 1977 Feb;37(2):535-40 [264412.001]
  • [Cites] J Med Chem. 2002 Oct 24;45(22):4913-22 [12383017.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] Biochem Pharmacol. 2003 Apr 1;65(7):1163-70 [12663051.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5929-37 [16135464.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] Mol Pharmacol. 1995 Sep;48(3):459-71 [7565626.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] Blood. 2007 May 15;109 (10 ):4164-7 [17264295.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):253-65 [15057285.001]
  • [Cites] N Engl J Med. 1986 Sep 11;315(11):657-63 [2943992.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(5):359-65 [8306408.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10 ):1293-302 [14499708.001]
  • [Cites] Cell Prolif. 1992 Nov;25(6):523-36 [1457603.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Carbohydr Res. 1985 Feb 28;136:391-6 [4005892.001]
  • [Cites] Invest New Drugs. 1999;17(1):81-7 [10555126.001]
  • [Cites] Lancet. 1987 Apr 4;1(8536):786-9 [2882192.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(6):461-70 [9788572.001]
  • [Cites] Leukemia. 1998 May;12(5):660-5 [9593262.001]
  • [Cites] Biochem Pharmacol. 2001 Apr 1;61(7):857-65 [11274972.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2039-44 [9447817.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):548 [16094758.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Nov;4(11):804-5 [17143248.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):649-55 [11531245.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1583-9 [8453627.001]
  • [Cites] Ann Pharmacother. 1997 May;31(5):616-24 [9161659.001]
  • [Cites] Invest New Drugs. 1986;4(1):85-105 [3516918.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81 [15173957.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] J Med Chem. 1994 Jul 8;37(14):2167-74 [8035423.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 9;11(13):1671-3 [11425534.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1013-8 [9028333.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] J Med Chem. 1993 Mar 19;36(6):758-64 [8459402.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):797-805 [12394263.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):293-9 [16856922.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):767-74 [15146568.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(4):351-5 [8548881.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7161-7 [16192600.001]
  • [Cites] Nat Genet. 2004 May;36(5):453-61 [15098032.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5766-74 [12411494.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1137-43 [9894715.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):199-203 [9428769.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):896-904 [7547237.001]
  • [Cites] J Med Chem. 2001 Dec 6;44(25):4416-30 [11728187.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):758-65 [7476904.001]
  • [Cites] Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9 [15117429.001]
  • [Cites] Adv Exp Med Biol. 1984;165 Pt B:309-14 [6609537.001]
  • [Cites] Cancer. 1976 Jan;37(1):220-8 [1061636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11598-602 [8265596.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2155-60 [8374873.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1277-83 [10368688.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1203-9 [10506705.001]
  • [Cites] Annu Rev Med. 1997;48:353-74 [9046968.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] J Med Chem. 1998 Dec 17;41(26):5310-9 [9857098.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):179-84 [11269745.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):120-7 [16331634.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35 [16322992.001]
  • [Cites] Int J Exp Pathol. 2002 Feb;83(1):21-38 [12059907.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72 (5):844-50 [9311603.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):697-705 [10080616.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):727-37 [9615712.001]
  • [Cites] Adv Exp Med Biol. 1993;338:461-4 [8304158.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]
  • [Cites] Cancer. 1994 May 15;73(10):2515-9 [8174048.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1702-6 [8137285.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1479-84 [8137251.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2449-56 [16258975.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:148-52 [1578919.001]
  • [Cites] Biochemistry. 1997 Apr 15;36(15):4399-411 [9109647.001]
  • [Cites] J Med Chem. 1991 Feb;34(2):574-9 [1995880.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):17-8 [16485343.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):982-92 [15709163.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):1206-12 [11504822.001]
  • [Cites] Biochem Pharmacol. 1996 May 17;51(10):1331-40 [8787549.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):14-20 [11148680.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1780-6 [8355045.001]
  • [Cites] Mol Cancer Ther. 2002 Feb;1(4):275-86 [12467223.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Expert Opin Investig Drugs. 2003 May;12(5):853-63 [12720495.001]
  • [Cites] Jpn J Cancer Res. 1998 Sep;89(9):954-62 [9818032.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S16-7 [15962527.001]
  • [Cites] Pediatr Nurs. 1995 Sep-Oct;21(5):471-4, 490 [8684851.001]
  • [Cites] Biochemistry. 1964 Jan;3:15-8 [14114497.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8 [12111105.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Biochem Biophys Res Commun. 1972 May 26;47(4):685-91 [5026289.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3036-50 [9679969.001]
  • [Cites] Cancer Res. 1976 Apr;36(4):1499-502 [1260766.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4341-4 [11389057.001]
  • [Cites] Hematol J. 2002;3(1):2-6 [11960387.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1843-9 [9816139.001]
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5(4):257-62 [16356302.001]
  • [Cites] Leuk Lymphoma. 1993;10 Suppl:153-7 [8481665.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3288-94 [16368880.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):583-7 [3282032.001]
  • [Cites] Cancer Res. 1990 Jul 15;50(14):4260-6 [2194651.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1421-3 [16601247.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 15;55(8):1229-34 [9719477.001]
  • (PMID = 17927282.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Folic Acid Antagonists; 0 / Nucleosides; 0 / Oncogene Proteins v-abl; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  • [Number-of-references] 159
  •  go-up   go-down


21. Guan LJ, Zhang JH, Wang YX, Zhang N, Hu YP, Li ZG, Zhao W: [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia].
  • In order to investigate the expression and the relationship of ubiquitin associated protein 1 (ubap1) gene and tumor-suppressor gene p16 in acute leukemia, 68 cases of acute leukemia and 22 control cases were selected in this experiment, FQ-PCR technique was used to detect the mRNA expression level of ubap1 gene and p16 gene in their bone marrow cells.
  • The results showed that as compared with the control group, the ubap1 gene in acute leukemia group highly expressed (p<0.01), while the p16 gene lowly expressed (p<0.01).
  • In addition to this, the ubap1 gene and p16 gene mRNA expression in AL was not relate with chromosome abnormality (p>0.05).
  • It is concluded that the upregulation of ubap1 gene expression mainly and the downregulation of p16 gene expression mainly may simultaneously participate in the pathogenesis of acute leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129243.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / UBAP1 protein, human
  •  go-up   go-down


22. Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, Steggerda S, Wheler J, Balasubramanian S, Chandra J: PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int J Cell Biol; 2010;2010:207420
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
  • In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC inhibitor, require caspase-8 and the adaptor molecule, Fas-associated death domain (FADD), in acute leukemia cells.
  • Taken together, these results provide insight into the mechanism of apoptosis induction by PCI-24781 in leukemia by highlighting the roles of caspase-8, FADD and increased superoxide levels.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12001-8 [11812781.001]
  • [Cites] FEBS J. 2009 Aug;276(15):4256-65 [19583773.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9231-42 [14647441.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1207-14 [15116122.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Cell Death Differ. 2005 Jan;12(1):10-8 [15540114.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1309-17 [16731764.001]
  • [Cites] Exp Mol Med. 2006 Dec 31;38(6):616-24 [17202837.001]
  • [Cites] Blood. 2007 Jul 1;110(1):267-77 [17356134.001]
  • [Cites] Nature. 2007 May 24;447(7143):433-40 [17522677.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20 [17594194.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):643-5 [17912024.001]
  • [Cites] Mol Med. 2008 Jan-Feb;14(1-2):20-7 [17973028.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):740-8 [18413789.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19499-510 [18458084.001]
  • [Cites] Antioxid Redox Signal. 2009 May;11(5):1123-37 [19018667.001]
  • [Cites] Blood. 2009 Jul 9;114(2):380-93 [19383971.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3354-65 [19417023.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4512-9 [12920036.001]
  • (PMID = 20145726.001).
  • [ISSN] 1687-8884
  • [Journal-full-title] International journal of cell biology
  • [ISO-abbreviation] Int J Cell Biol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115811
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2817379
  •  go-up   go-down


23. Georgy M, Yonescu R, Griffin CA, Batista DA: Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults. Cancer Genet Cytogenet; 2008 Aug;185(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults.
  • Acute mixed lineage leukemia (AMLL) is a rare form of leukemia in which both myeloid and lymphoid markers are present.
  • Few chromosome abnormalities have been identified associated with this form of leukemia.
  • A translocation involving the long arms of chromosomes 6 and 14 was previously described in four young individuals with acute leukemia and in three of these cases the diagnosis was mixed lineage.
  • The rarity of the t(6;14) and the AMLL suggests a non-random association between these two events.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 6. Leukemia, Biphenotypic, Acute / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656690.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Styczynski J, Gil L, Derwich K, Wachowiak J, Balwierz W, Badowska W, Krawczuk-Rybak M, Matysiak M, Wieczorek M, Balcerska A, Sonta-Jakimczyk D, Stefaniak J, Kowalczyk J, Urasinski T, Sobol G, Komarnicki M, Wysocki M: Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res; 2009 May;29(5):1643-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
  • The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • PATIENTS AND METHODS: The ex vivo drug resistance profile was analyzed in 282 patients, including 201 children with ALL de novo, 24 children with relapsed ALL, 25 children with AML de novo and 32 adults with AML.
  • RESULTS: Clofarabine had comparable ex vivo activity against lymphoblasts and myeloblasts, both on initial diagnosis and at relapse, both in children and in adults.
  • Its activity in acute myeloid leukemia was independent of patient age.
  • CONCLUSION: In comparison to childhood acute lymphoblastic leukemia, lack of differences in ex vivo activity gives rationale for use of clofarabine in refractory and relapsed pediatric and adult patients with acute myeloid leukemia.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443380.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


25. Tajeddine N, Millard I, Gailly P, Gala JL: Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med; 2006;44(5):548-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
  • BACKGROUND: Specific gene rearrangements are used for minimal residual disease (MRD) assessment, but are frequently lacking in leukaemias.
  • Basal expression of PRAME was determined in 25 blood samples and 25 bone marrow samples from healthy donors, as well as in 12 haematological cell lines (Jurkat, K562, HL60, DOHH2, IM9, Daudi, CEM, KG1, DG75, 8226, U937, Raji).
  • RESULTS: In paediatric acute myeloid leukaemia (AML) (n=22) and acute lymphoblastic leukaemia (ALL) (n=17), and in adult AML (n=20), abnormal PRAME expression was found in 41%, 35% and 40% of cases, respectively.
  • CONCLUSIONS: Our data confirm that PRAME quantification by real-time RT-PCR appears suitable for monitoring MRD in PRAME-positive leukaemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681423.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / PRAME protein, human
  •  go-up   go-down


26. Matsushita M, Yamazaki R, Ikeda H, Mori T, Sumimoto H, Fujita T, Okamoto S, Ikeda Y, Kawakami Y: Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Br J Haematol; 2006 Jan;132(1):56-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
  • Cytotoxic T lymphocyte (CTL) lines specific for allogeneic antigens were generated by in vitro stimulation of donor-derived peripheral blood mononuclear cells obtained from patients who received human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplantation (HSCT).
  • One of the allogeneic antigen-specific CD4+ CTL lines, CTL-A, generated from a patient with T cell acute lymphoblastic leukaemia, recognised HLA-DPB1*0501-positive Epstein-Barr virus-immortalised human B cell line (EBV-B cells), phytohaemagglutinin blasts and leukaemia cells, but not interferon-gamma (IFN-gamma) treated HLA-DPB1*0501-positive fibroblasts, indicating that this CD4+ T-cell line recognised a minor histocompatibility antigen (mHa) that is preferentially expressed in haematopoietic cells in an HLA-DPB1*0501-restricted manner.
  • The other CD4+ CTL line, CTL-B, generated from a patient with chronic myeloid leukaemia, recognised mismatched HLA-DQB1*0303 on EBV-B cells and phytohaemagglutinin (PHA) blasts.
  • Interestingly, this CTL line did not recognise IFN-gamma-treated recipient's skin fibroblasts, as HLA-DQ was merely upregulated even after IFN-gamma stimulation in non-haematopoietic cells including fibroblasts, endothelial cells and hepatocytes.
  • These results suggest that these CD4 positive CTLs, specific for mismatch HLA-DQ and mHa that are preferentially expressed on haematopoietic cells, may play an important role in induction of selective graft-versus-leukaemia effect without development of graft-versus-host disease after allogeneic HSCT.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Graft vs Leukemia Effect / immunology. Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Cell Line, Transformed. Cell Transformation, Viral. Epitopes, T-Lymphocyte / immunology. Female. Genes, MHC Class II. Graft vs Host Disease / prevention & control. HLA-DP Antigens / analysis. HLA-DQ Antigens / analysis. Herpesvirus 4, Human. Histocompatibility Testing. Humans. Interferon-gamma / immunology. Leukemia / immunology. Male. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371020.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Epitopes, T-Lymphocyte; 0 / HLA-DP Antigens; 0 / HLA-DQ Antigens; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


27. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, Olofsson T, Råde J, Fontes M, Porwit-Macdonald A, Behrendtz M, Höglund M, Johansson B, Fioretos T: Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia; 2007 Jun;21(6):1198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status.
  • Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute lymphoblastic leukemias (ALLs), 11 T-cell ALLs and 23 acute myeloid leukemias (AMLs)), investigated during an 8-year period at a single center.
  • Minimal residual disease status (MRD) in T-cell ALLs with a high (>0.1%) MRD at day 29 could be classified with 100% accuracy already at the time of diagnosis.
  • In pediatric leukemias with uncharacteristic cytogenetic aberrations or with a normal karyotype, unsupervised analysis identified two novel subgroups: one consisting mainly of cases remaining in complete remission (CR) and one containing a few patients in CR and all but one of the patients who relapsed.
  • This study of a consecutive series of childhood leukemias confirms and extends further previous reports demonstrating that global gene expression profiling provides a valuable tool for genetic and clinical classification of childhood leukemias.
  • [MeSH-major] Leukemia / classification. Leukemia / genetics. Neoplasm, Residual / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Acute Disease. Algorithms. Child. Gene Expression Profiling. Genes, cdc. Humans. Leukemia, B-Cell. Leukemia, Myeloid. Leukemia, T-Cell. Predictive Value of Tests. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410184.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


28. Loh AH, Chui CH: Port-A-Cath insertions in acute leukaemia and childhood malignancies. Asian J Surg; 2007 Jul;30(3):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-A-Cath insertions in acute leukaemia and childhood malignancies.
  • Incidence of catheter-related bloodstream infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with acute leukaemia versus other malignancies.
  • While mean preoperative platelet count was 125.34 x 10(9)/L in children with acute leukaemia and 392.11 x 10(9)/L in those with other malignancies (p < 0.01), the incidence of all complications were similar between both subgroups.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638639.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Kubiak-Wlekły A, Niemir ZI: [The relevance of neprilysin for systemic homeostasis and its involvement in the pathological processes]. Pol Merkur Lekarski; 2009 Jul;27(157):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neprilysin (NEP, CD10, CALLA-common acute lymphoblastic leukaemia antigen, neutral endopeptidase, enkephalinase) is a zinc-dependent metallopeptidase, which is involved in the metabolism of a number of regulatory peptides and plays an important role in turning off peptide signalling at the cell surface.
  • It regulates blood pressure and inflammatory response, takes part in the pathogenesis of Alzheimer disease, influences cellular proliferation and differentiation, as well as neoplastic progression.
  • [MeSH-minor] Alzheimer Disease / metabolism. Animals. Blood Pressure / physiology. Cell Differentiation / physiology. Cell Division / physiology. Disease Progression. Humans. Inflammation / physiopathology. Neoplasms / physiopathology. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650431.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 40
  •  go-up   go-down


30. Pop-Jora D, Berhoune C, Najioullah F, Girard S, Mialou V, Bleyzac N, Galambrun C, Bertrand Y: [Human herpesvirus 6 encephalitis after bone marrow transplantation]. Arch Pediatr; 2006 Dec;13(12):1518-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Un cas d'encéphalite à herpès virus humain de type 6 après transplantation de moelle osseuse.
  • Human herpesvirus 6 (HHV-6) encephalitis may induce neurological sequelae and death; the diagnosis is difficult because of an initially poor symptomatology and of the absence of specific biochemical, electric and radiological signs.
  • We report on a 7-year-old boy with relapsed acute lymphoblastic leukaemia, who developed HHV-6 encephalitis after bone marrow transplantation; the patient recovered after treatment with ganciclovir.
  • [MeSH-minor] Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Child. Follow-Up Studies. Ganciclovir / administration & dosage. Ganciclovir / therapeutic use. Graft vs Host Disease / complications. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092696.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


31. Shah A, Stiller C, Lancaster D, Vincent T, Coleman MP: Leukaemia survival trends in children with Down's syndrome in Great Britain, 1971-2000: a population-based study. J Epidemiol Community Health; 2010 Jul;64(7):604-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia survival trends in children with Down's syndrome in Great Britain, 1971-2000: a population-based study.
  • BACKGROUND: Children with Down's syndrome (DS) who developed leukaemia have had a worse prognosis than other children with leukaemia in the past.
  • In the 1970s and early 1980s, some children with DS who developed leukaemia received fewer cycles of chemotherapy or were advised not to have treatment.
  • METHODS: In this population-based study, trends in 5-year survival from leukaemia were evaluated for children with and without DS who were diagnosed in Great Britain during 1971-2000 and followed to the end of 2004.
  • For lymphoid leukaemia, survival in children with DS increased, but remains lower than for other children (5-year survival 59% vs 83% during 1996-2000).
  • For acute non-lymphoblastic leukaemia (ANLL), however, 5-year survival improved substantially for children with DS, from less than 1% in the early 1970s to over 80% in the 1990s.
  • CONCLUSION: Survival for all children diagnosed with leukaemia has improved during the last three decades.
  • For lymphoid leukaemia, the inferior outcome observed on more recent treatment protocols in children with DS remains an area for concern.
  • For ANLL, the improvement in survival for children with DS is due to a number of factors, namely increased recruitment of these children to clinical trials, changes in clinical practice and important differences in the biology of myeloid leukaemia in young children with DS, resulting in a better response to some chemotherapeutic agents.
  • [MeSH-major] Down Syndrome / mortality. Leukemia / mortality

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703908.001).
  • [ISSN] 1470-2738
  • [Journal-full-title] Journal of epidemiology and community health
  • [ISO-abbreviation] J Epidemiol Community Health
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø: Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs; 2009 Apr;18(4):433-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapy in acute myeloid leukaemia: current status and future directions.
  • BACKGROUND: The limit of acceptable toxicity for standard chemotherapeutic drugs used in acute myeloid leukaemia (AML) therapy has been reached.
  • OBJECTIVE: This review summarizes development in new strategies, and gives an overview of the clinical status on new drugs for non-promyelocytic AML in adults.
  • RESULTS/CONCLUSION: The major improvements in AML treatment during the last two decades has not been the introduction of new therapeutic agents, but rather the more optimal use of well-known drugs (e.g., high-dose cytarabine therapy, the use of ATRA in maintenance therapy of acute promyelocytic leukaemia) and improvement in the diagnosis and treatment of potentially life-threatening complications in patients treated with allogeneic stem cell transplantation.
  • However, further investigations based on specific targeted therapy and stratification of patients according to knowledge of the individual disease and health status will probably be necessary in future studies of new targeted therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Design. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335274.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors
  • [Number-of-references] 234
  •  go-up   go-down


33. Franklin JG, Paus MD, Pluetschow A, Specht L: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev; 2005;(4):CD003187
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.
  • BACKGROUND: Second malignancies (SM) are a major late effect of treatment for Hodgkin's disease (HD).
  • OBJECTIVES: Radiotherapy (RT), chemotherapy (CT) and combined chemo-radiotherapy (CRT) for newly-diagnosed Hodgkin's disease are compared with respect to SM risk, overall (OS) and progression-free (PFS) survival.
  • Secondary acute leukemia (AL), non-Hodgkin's lymphoma (NHL) and solid tumours (ST) were also analysed separately.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235316.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 127
  •  go-up   go-down


34. Mlombie Y: Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward. Malawi Med J; 2010 Jun;22(2):59-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward.
  • [MeSH-major] Burkitt Lymphoma. Leukemia
  • [MeSH-minor] Acute Disease. Humans. Malawi. Practice Patterns, Physicians' / trends

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1975 Feb;19(2):201-8 [1240046.001]
  • [Cites] S Afr Med J. 2009 Apr;99(4):243-8 [19588777.001]
  • [CommentOn] Malawi Med J. 2009 Jun;21(2):86, 88-9 [20345012.001]
  • (PMID = 21618748.001).
  • [ISSN] 1995-7262
  • [Journal-full-title] Malawi medical journal : the journal of Medical Association of Malawi
  • [ISO-abbreviation] Malawi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Malawi
  • [Other-IDs] NLM/ PMC3345756
  •  go-up   go-down


35. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR: Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol; 2010 Dec;151(5):430-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
  • Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia.
  • The median age was 41 years, 44% of patients were either in ≥2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Apr 1;109(7):3080-3 [17170128.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):806-13 [17341266.001]
  • [Cites] Semin Oncol. 2007 Dec;34(6 Suppl 5):S13-20 [18086342.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2927-35 [18483359.001]
  • [Cites] J Cell Physiol. 2000 Jan;182(1):119-26 [10567923.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):110-6 [11801546.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Development. 2003 Jun;130(12):2779-91 [12736220.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] Development. 2004 May;131(9):2137-47 [15105373.001]
  • [Cites] Mol Pharmacol. 1988 Oct;34(4):485-91 [3050447.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Semin Hematol. 1991 Jul;28(3 Suppl 4):84-9 [1780759.001]
  • [Cites] Mol Biol Cell. 1993 Jun;4(6):637-45 [8374172.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1347-55 [9815818.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):515-20 [10051535.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3058-63 [15217837.001]
  • [Cites] Leukemia. 2005 Jan;19(1):64-8 [15510196.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55958-68 [15496414.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):8-20 [17910043.001]
  • (PMID = 21113977.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / CA073590; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA073590; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA058861
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / CTGF protein, human; 0 / Neoplasm Proteins; 0 / Nucleoside Transport Proteins; 04079A1RDZ / Cytarabine; 139568-91-5 / Connective Tissue Growth Factor; 762RDY0Y2H / clofarabine
  • [Other-IDs] NLM/ NIHMS244575; NLM/ PMC3058291
  •  go-up   go-down


36. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O, Developmental Committee of the European Group for Blood and Marrow Transplantation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet; 2008 May 10;371(9624):1579-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
  • BACKGROUND: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic transplantation with haemopoietic stem cells.
  • We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation.
  • METHODS: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II experimental study.
  • Three patients had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin.
  • Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with partial or no response (11 [37%] of 30 vs 18 [72%] of 25; p=0.002) and higher overall survival 2 years after haemopoietic-stem-cell transplantation (16 [53%] of 30 vs four [16%] of 25; p=0.018).
  • INTERPRETATION: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD.
  • [MeSH-major] Graft vs Host Disease / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Mesenchymal Stem Cell Transplantation

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2008 May 10;371(9624):1553-4 [18468526.001]
  • (PMID = 18468541.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Thomas X, Campos L, Le QH, Guyotat D: Heat shock proteins and acute leukemias. Hematology; 2005 Jun;10(3):225-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock proteins and acute leukemias.
  • HSPs have also been implicated in the resistance of leukemia cells to potential therapeutic agents.
  • HSPs were shown highly expressed by acute myeloid leukemia (AML) cells as well as by acute lymphoblastic leukemia (ALL) cells.
  • [MeSH-major] Antineoplastic Agents / metabolism. Gene Expression Regulation, Leukemic / drug effects. HSP90 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Rifabutin / analogs & derivatives

  • Hazardous Substances Data Bank. RIFABUTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019471.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Neoplasm Proteins; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin
  • [Number-of-references] 122
  •  go-up   go-down


38. Ennis MK, Dingli D: Death by fusion for acute leukemia cells. Cancer Biol Ther; 2010 Mar 1;9(5):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death by fusion for acute leukemia cells.
  • [MeSH-major] Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Biol Ther. 2010 Mar 1;9(5):350-7 [20061812.001]
  • (PMID = 20104027.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


39. Li R, Cao XH, Liu C, Wu XL, Ling YW, Zhang Y, Feng R, Liu QF: [Clinical implications of HLA-G protein expression in acute leukemia]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2446-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical implications of HLA-G protein expression in acute leukemia].
  • OBJECTIVE: To detect the expression of membrane-bound HLA-G (mHLA-G) and serum HLA-G (sHLA-G) in acute leukemia patients and investigate the correlation between HLA-G expression and the occurrence and development of acute leukemia.
  • METHODS: Enzyme-linked immunosorbent assay and flow cytometry were used to detect the expression levels of sHLA-G and mHLA-G in 40 newly diagnosed leukemia cases, 10 refractory and relapsed leukemia cases, and 30 leukemia cases receiving chemotherapy.
  • RESULTS: The mean serum level of sHLA-G in normal individuals was 5.87±2.07 ng/ml, as compared to 10.05±6.58 ng/ml in newly diagnosed leukemia patients and 12.32±5.85 ng/ml in refractory and relapsed cases.
  • CONCLUSION: HLA-G expression levels might influence the treatment outcomes and can serve as a prognostic factor for acute leukemia.
  • [MeSH-major] HLA-G Antigens / metabolism. Leukemia / metabolism. Leukemia / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097401.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-G Antigens
  •  go-up   go-down


40. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, Campana D, Koscielniak E, Niemeyer C, Schlegel PG, Müller I, Niethammer D, Bader P: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol; 2005 Mar;128(6):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
  • Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).
  • Leukaemia-associated immunophenotypes, at a sensitivity of MRD detection by FC at the 0.01% level, were identified in 41 cases (91%); antigen-receptor gene rearrangements suitable for MRD detection with a sensitivity of 0.01% or better by PCR were identified in 38 cases (84%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Flow Cytometry / methods. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755280.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Stack M, Walsh PM, Comber H, Ryan CA, O'Lorcain P: Childhood cancer in Ireland: a population-based study. Arch Dis Child; 2007 Oct;92(10):890-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Observed 5-year survival in Ireland (79% overall) was slightly higher than European and US averages, and was significantly higher for acute non-lymphocytic leukaemia (67%) and (compared with the USA) significantly lower for Hodgkin lymphoma (83%).
  • [MeSH-major] Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):785-809 [11311655.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] Ir Med J. 1992 Jun;85(2):50-2 [1628939.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3742-51 [15923571.001]
  • [Cites] Ir Med J. 1995 May-Jun;88(3):96-8 [7635688.001]
  • (PMID = 17566053.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2083220
  •  go-up   go-down


42. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B: Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol; 2008 May;30(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
  • At concentrations >0.1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro.
  • This study of children with refractory acute leukemia was designed to take advantage of this biochemical modulation.
  • Thirty-three children [26 acute lymphocytic leukemia (ALL), 7 acute nonlymphocytic leukemia] were treated; 29 received at least 1 full course.
  • There were 6 complete responses (5 ALL), 5 partial responses (3 ALL), and 19 patients with no response or progressive disease.
  • This combination of HU and ara-C is tolerable and has efficacy in refractory leukemias.
  • [MeSH-major] Cytarabine / toxicity. Hydroxyurea / toxicity. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infection / epidemiology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality. Liver / drug effects. Liver / pathology. Skin / drug effects. Skin / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458568.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ NIHMS721202; NLM/ PMC4601800
  •  go-up   go-down


43. van Hirtum PV, Prins M, ten Oever J, Nijziel MR, Vreugdenhil G, Dercksen MW: [Sweet syndrome in underlying malignancy]. Ned Tijdschr Geneeskd; 2010;154:A2112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Syndroom van Sweet bij onderliggende maligniteit.
  • Sweet syndrome, also known as acute febrile neutrophilic dermatosis, was diagnosed in two patients.
  • Patient A, a 68-year-old man, had had chronic lymphatic leukaemia for four years, with a recent relapse.
  • Patient B, a 58-year-old man, had been diagnosed with renal cell carcinoma four years earlier.
  • Both patients presented with general discomfort, high fever, neutrophilic leukocytosis and diffuse, non-tender maculopapular exanthema, partly blanching on applied pressure, and vesicles spread over the body.
  • Patient A had clinical signs of a septic shock.
  • In patient B, progression of renal cell carcinoma was found more than a half year later.
  • It is important to recognise the varied clinical picture of the rare disorder that is Sweet syndrome because it can lead to severe clinical illness, especially in patients with an underlying malignancy.
  • [MeSH-major] Neoplasms / complications. Prednisone / therapeutic use. Sweet Syndrome / diagnosis. Sweet Syndrome / drug therapy. Sweet Syndrome / etiology
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / diagnosis. Disease Progression. Follow-Up Studies. Humans. Kidney Neoplasms / diagnosis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21040604.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] VB0R961HZT / Prednisone
  •  go-up   go-down


44. Berköz M, Yalin S: Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res; 2009 Jul;33(7):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.
  • In this study, we aimed to determine whether any association exists between genetic polymorphism in CYP2B6G15631T and individual susceptibility to acute leukemia.
  • Our study group consisted of 80 acute leukemia patients and 100 unrelated healthy volunteers as a control group.
  • 44 of the acute leukemia patients were diagnosed with acute lymphoblastic leukemia (ALL) and 36 patients with acute myeloid leukemia (AML).
  • The frequencies of GG genotype (wild type) were 40.9%, 50% and 67% in ALL, AML and control groups, respectively.
  • The TT genotype (homozygous variant) was not observed in either control or leukemia cases.
  • Logistic regression analyses showed a significant correlation between the CYP2B6 G15631T polymorphism (GT) and acute leukemia patients (OR=2.481, 95% CI=1.353-4.551, p=0.003).
  • Our findings indicate that GT genotype may be an important genetic determinant for acute leukemias.
  • According to our knowledge, this is the first report of an association between acute leukemia cases and the CYP2B6 G15631T polymorphism.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Leukemia, Myeloid, Acute / genetics. Oxidoreductases, N-Demethylating / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Cytochrome P-450 CYP2B6. DNA, Neoplasm / genetics. Disease Susceptibility. Genotype. Humans. Middle Aged. Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144407.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


45. Bacher U, Kohlmann A, Haferlach T: Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol; 2009 Jun;145(5):555-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
  • Gene expression profiling (GEP) enables the simultaneous investigation of the expression of tens of thousands of genes and was successfully introduced in leukaemia research a decade ago.
  • Aiming to better understand the diversity of genetic aberrations in acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), pioneer studies investigated and confirmed the predictability of many cytogenetic and molecular subclasses in AML and ALL.
  • In addition, GEP can define new prognostic subclasses within distinct leukaemia subgroups, as illustrated in AML with normal karyotype.
  • Finally, GEP might enable the detection of new molecular targets for therapy in patients with acute leukaemia.
  • Meanwhile, large multicentre studies, e.g. the Microarray Innovations in LEukaemia (MILE) study, prepare for a standardised introduction of GEP in leukaemia diagnostic algorithms, aiming to translate this novel methodology into clinical routine for the benefit of patients with the complex disorders of AML and ALL.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Gene Expression. Gene Rearrangement. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344393.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 118
  •  go-up   go-down


46. Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM, QUIT Study (PETHEMA, GELTAMO and GOTEL Groups): Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc); 2008 Oct 4;131(11):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
  • BACKGROUND AND OBJECTIVE: Central nervous system (CNS) involvement in patients diagnosed with acute leukemias (AL) is an uncommon complication with poor prognosis.
  • For acute lymphoblastic leukemia patients (n = 158), CNS therapy was given to 12 cases (10 at diagnosis and 2 at relapse) and consisted of triple intrathecal therapy (TIT, methotrexate, cytarabine and hydrocortisone) in 11 and liposomal depot cytarabine in one.
  • In acute myeloblastic leukemia patients (n = 107), CNS therapy was administered to 17 cases (9 at diagnosis and 8 at relapse).
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Registries

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928719.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


47. Blazkova H, Krejcikova K, Moudry P, Frisan T, Hodny Z, Bartek J: Bacterial intoxication evokes cellular senescence with persistent DNA damage and cytokine signalling. J Cell Mol Med; 2010 Jan;14(1-2):357-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammalian cells exposed to CDTs undergo cell type-dependent cell-cycle arrest or apoptosis; however, the cell fate responses to such intoxication are mechanistically incompletely understood.
  • Here we show that both normal and cancer cells (BJ, IMR-90 and WI-38 fibroblasts, HeLa and U2-OS cell lines) that survive the acute phase of intoxication by Haemophilus ducreyi CDT possess the hallmarks of cellular senescence.
  • This characteristic phenotype included persistently activated DNA damage signalling (detected as 53BP1/gammaH2AX(+) foci), enhanced senescence-associated beta-galactosidase activity, expansion of promyelocytic leukaemia nuclear compartments and induced expression of several cytokines (especially interleukins IL-6, IL-8 and IL-24), overall features shared by cells undergoing replicative or premature cellular senescence.
  • We conclude that analogous to oncogenic, oxidative and replicative stresses, bacterial intoxication represents another pathophysiological stimulus that induces premature senescence, an intrinsic cellular response that may mechanistically underlie the 'distended' morphology evoked by CDTs.
  • Finally, the activation of the two anticancer barriers, apoptosis and cellular senescence, together with evidence of chromosomal aberrations (micronucleation) reported here, support the emerging genotoxic and potentially oncogenic effects of this group of bacterial toxins, and warrant further investigation of their role(s) in human disease.
  • [MeSH-major] Bacterial Toxins / pharmacology. Cell Aging / physiology. Cell Line, Tumor. Cytokines / metabolism. DNA Damage. Signal Transduction / physiology
  • [MeSH-minor] Cell Cycle / drug effects. Cyclin-Dependent Kinases / antagonists & inhibitors. Cyclin-Dependent Kinases / metabolism. Haemophilus ducreyi / metabolism. Humans. Phenotype

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650831.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Cytokines; 0 / cytolethal distending toxin; EC 2.7.11.22 / Cyclin-Dependent Kinases
  • [Other-IDs] NLM/ PMC3837606
  •  go-up   go-down


48. Ferrara F, Palmieri S, Pedata M, Viola A, Izzo T, Criscuolo C, Mele G: Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol Oncol; 2009 Mar;27(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
  • Different studies have suggested the potential utility of autologous stem cell transplantation (ASCT) in acute myeloid leukaemia (AML) of the elderly with encouraging results in selected patients.
  • After a median follow-up of 25 months, median disease free and overall survival (OS) for the whole patient population were 13 and 22 months, respectively.
  • Our data confirm the feasibility of a conditioning regimen based on high-dose idarubicin plus busulphan in older selected AML patients and suggest clinical improvement in patients with normal cytogenetics.
  • [MeSH-major] Busulfan / therapeutic use. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / surgery
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Stem Cell Transplantation / methods. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 John Wiley & Sons, Ltd.
  • (PMID = 19206083.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
  •  go-up   go-down


49. Blalock WL, Bavelloni A, Piazzi M, Faenza I, Cocco L: A role for PKR in hematologic malignancies. J Cell Physiol; 2010 Jun;223(3):572-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a subset of myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia contain low levels of PKR expression and activity, elevated PKR activity and/or expression have been detected in a wide range of hematologic malignancies, from bone marrow failure disorders to acute leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20232306.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


50. Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH: cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. Int J Oncol; 2006 May;28(5):1065-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology and clinical course.
  • In an attempt to address this question, we performed cDNA microarray analysis on peripheral blood samples of 25 patients with newly diagnosed AML with high blast counts.
  • Leave-one-out crossvalidation (LOOCV) showed with high accuracy that gene expression classifiers could predict if leukaemia samples belonged to the FAB AML-M1 or to the FAB AML-M2 groups.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged


51. Soylu AR, Buyukasik Y, Cetiner D, Buyukasik NS, Koca E, Haznedaroglu IC, Ozcebe OI, Simsek H: Overt gastrointestinal bleeding in haematologic neoplasms. Dig Liver Dis; 2005 Dec;37(12):917-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Patients with acute leukaemia suffer from various haemorrhages, most frequently due to thrombocytopenia.
  • We could not reach any information regarding the frequency of gastrointestinal bleeding in acute leukaemia and decided to search this complication in patients with acute and chronic leukaemias and myeloproliferative disorders, retrospectively.
  • PATIENTS AND METHODS: During a 6-year period, 291 patients with acute leukaemia, 52 patients with chronic leukaemia and 108 patients with myeloproliferative disorders had been followed.
  • RESULTS: The frequency of bleeding episodes was 7.1% (32/451) in haematologic malignancies as a whole, 5.8% (17/291) for acute leukaemia, 1.9% (1/52) for chronic leukaemia and 13% (14/108) for myeloproliferative disorders.
  • Five out of the seven patients had acute leukaemia.
  • All of the mortality cases were patients with acute leukaemia.
  • Lower gastrointestinal bleeding is frequently a problem of the patients with acute leukaemia.
  • [MeSH-major] Gastrointestinal Hemorrhage / epidemiology. Hematologic Neoplasms / complications. Leukemia / complications. Myeloproliferative Disorders / complications

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243010.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Wei J, Xiao Y, Yu X, Zhou J, Zhang Y: Early onset of syndrome of inappropriate antidiuretic hormone secretion (SIADH) after allogeneic haematopoietic stem cell transplantation: case report and review of the literature. J Int Med Res; 2010 Mar-Apr;38(2):705-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early onset of syndrome of inappropriate antidiuretic hormone secretion (SIADH) after allogeneic haematopoietic stem cell transplantation: case report and review of the literature.
  • Severe hyponatraemia and syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a rare but fatal complication following stem cell transplantation (SCT).
  • The patient, who had chronic myelogenous leukaemia, developed acute graft-versus-host disease (GVHD) on day 5 after allo-HSCT, which was relieved promptly by steroids.
  • The severity of the disorder is underestimated because of the non-specific clinical features and the lack of effective treatment.
  • Myeloablative conditioning and acute GVHD are two major important predisposing factors in SIADH.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Inappropriate ADH Syndrome / etiology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adult. Fatal Outcome. Graft vs Host Disease / etiology. Humans. Male. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515586.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


53. Chen XW, Yue LJ, Li CG, Li CR, Zhang M, Shi HS: [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia].
  • This study investigated the allelic frequencies and distribution characters of single-nucleotide polymorphisms within the coding region (cSNPs) of TS gene in Chinese children with acute leukemia (AL) and normal control children in order to explore the possible relationship between the cSNP in human TS gene and chemotherapeutic effects of 5-fluorouracils.
  • [MeSH-major] Leukemia / genetics. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction / methods. Thymidylate Synthase / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Electrophoresis, Polyacrylamide Gel. Female. Humans. Infant. Infant, Newborn. Male. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374805.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


54. Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, Xu X, Li Y, Christiani DC, Kaohsiung Leukemia Research Group: Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC Cancer; 2009 Jan 13;9:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study.
  • This study investigated whether consumed cured/smoked meat and fish, the major dietary resource for exposure to nitrites and nitrosamines, is associated with childhood acute leukemia.
  • 145 acute leukemia cases and 370 age- and sex-matched controls were recruited between 1997 and 2005.
  • RESULTS: Consumption of cured/smoked meat and fish more than once a week was associated with an increased risk of acute leukemia (OR = 1.74; 95% CI: 1.15-2.64).
  • No statistically significant association was observed between leukemia risk and the consumption of pickled vegetables, fruits, and tea.
  • CONCLUSION: Dietary exposure to cured/smoked meat and fish may be associated with leukemia risk through their contents of nitrites and nitrosamines among children and adolescents, and intake of vegetables and soy-bean curd may be protective.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:79-82 [12505288.001]
  • [Cites] Comp Biochem Physiol A Comp Physiol. 1989;93(1):285-90 [2568231.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5111-7 [2548712.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):541-6 [1672382.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):139-46 [8461864.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):195-202 [8167267.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):790S-797S [7533831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):901-6 [8922298.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Radiat Environ Biophys. 1998 Feb;36(4):217-28 [9523337.001]
  • [Cites] Cancer Causes Control. 1998 Dec;9(6):553-7 [10189040.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):163-5 [15540221.001]
  • [Cites] Free Radic Biol Med. 2005 Jul 15;39(2):257-65 [15964517.001]
  • [Cites] Nutr Cancer. 2006;54(1):111-42 [16800779.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Nutr Cancer. 2006;56(2):225-31 [17474869.001]
  • [Cites] J Nutr. 2008 Apr;138(4):775-81 [18356334.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):984-90 [18339682.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • [Cites] Am J Epidemiol. 1999 Nov 1;150(9):930-8 [10547138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8 [12869409.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):667-71 [15158086.001]
  • [Cites] Free Radic Biol Med. 2004 Jun 15;36(12):1505-16 [15182853.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Ann N Y Acad Sci. 1980;355:267-79 [6940481.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(1):7-10 [3903369.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):603-9 [10797279.001]
  • [Cites] J Nutr. 2000 Aug;130(8):1887-93 [10917898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1051-8 [11045787.001]
  • [Cites] Free Radic Res. 2001 Sep;35(3):215-31 [11697121.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):777-81 [12163333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):815-21 [12223424.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Mar;24(3):403-11 [3383943.001]
  • (PMID = 19144145.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00002; United States / NIEHS NIH HHS / ES / ES09723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653540
  • [Investigator] Chang TT; Lin SF; Chiou SS; Jang RC; Hsiao HH; Liu TC; Lin PC; Hsiao CC; Sheen JM; Kuo CY; Wang MC; Huang CH; Huang CB; Wong YC; Wu HB; Lin SJ; Sun YM; Hsieh KS; Chang YH
  •  go-up   go-down


55. Wang H, Gao ZQ, Li YL, Liu W, Quan SM: [Bilateral facial nerve paralysis-diagnosis and treatment]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Nov;41(11):821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral facial nerve paralysis-diagnosis and treatment].
  • OBJECTIVE: To observe the ways of diagnosis and treatment of bilateral facial nerve palsy.
  • METHODS: Seven cases of bilateral facial nerve paralysis in 1996 - 2003 were retrospectively reviewed, and then the ways of diagnosis and therapies of these cases were analyzed.
  • There were 6 patients with doubtless diagnosis.
  • They were diagnosed as acute leukaemia, Vogt-Koyanagi-Harada disease (VKH), Machado-Jesoph disease, bilateral mandible fractures, Guillain-Barré syndrome, and Bell's palsy.
  • The last one was diagnosed as Herpes zoster virus infection or Lyme disease.
  • CONCLUSIONS: Bilateral facial nerve paralysis was rare, and it was difficult to diagnosis and differentiation, while diagnostic mistakes would be serious.

  • Genetic Alliance. consumer health - paralysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283534.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


56. Rossbach HC: Diagnostic pitfalls in acute leukemia. Fetal Pediatr Pathol; 2009;28(2):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic pitfalls in acute leukemia.
  • In most children presenting with the common signs and symptoms of leukemia, the diagnosis is readily made.
  • However, unusual features of the disease and the absence of abnormalities on the complete blood count may render the diagnosis problematic, especially if this malignancy is not suspected.
  • The current report focuses on the unusual presentation of leukemia and the difficulties in the diagnosis of the malignancy.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Bone Marrow Cells / pathology. Child. Humans. Liver / pathology. Skin Diseases / etiology. Spinal Cord Compression / etiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241238.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Golembe TJ, Yong J, Battle DJ, Feng W, Wan L, Dreyfuss G: Lymphotropic Herpesvirus saimiri uses the SMN complex to assemble Sm cores on its small RNAs. Mol Cell Biol; 2005 Jan;25(2):602-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymphotropic Herpesvirus saimiri (HVS) causes acute leukemia, T-cell lymphoma, and death in New World monkeys.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5631-6 [11714716.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1023-9 [9323130.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):1188-96 [11867547.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8243-7 [11756452.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):720-8 [11914277.001]
  • [Cites] Semin Pediatr Neurol. 2002 Jun;9(2):145-50 [12138998.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31957-62 [12065586.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5853-63 [12411503.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1775-9 [12459587.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 Jan;4(1):74-80 [14683633.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2747-56 [15024064.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4522-33 [15121869.001]
  • [Cites] EMBO J. 1982;1(10):1259-65 [6202507.001]
  • [Cites] Hum Mol Genet. 1999 Dec;8(13):2351-7 [10556282.001]
  • [Cites] J Virol. 1999 Dec;73(12):10551-5 [10559377.001]
  • [Cites] J Cell Biol. 1999 Dec 13;147(6):1181-94 [10601333.001]
  • [Cites] J Virol. 2000 Jan;74(2):1033-7 [10623770.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1177-86 [10725331.001]
  • [Cites] Hum Mol Genet. 2000 Aug 12;9(13):1977-86 [10942426.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26370-5 [10851237.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):75-85 [11149922.001]
  • [Cites] Nature. 2001 Jan 25;409(6819):539-42 [11206553.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9599-605 [11121410.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):545-67 [11313011.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):290-301 [11343899.001]
  • [Cites] Biochem Soc Trans. 2001 May;29(Pt 2):15-26 [11356120.001]
  • [Cites] Mol Cell. 2001 May;7(5):1111-7 [11389857.001]
  • [Cites] Curr Biol. 2001 Jul 24;11(14):1079-88 [11509230.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5443-52 [11574476.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38645-51 [11509571.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8289-300 [11713266.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):945-9 [11715014.001]
  • [Cites] Curr Biol. 2001 Dec 11;11(24):1990-4 [11747828.001]
  • [Cites] EMBO J. 1986 Jul;5(7):1625-32 [2427336.001]
  • [Cites] Cell. 1988 Aug 26;54(5):599-607 [2842058.001]
  • [Cites] Nucleic Acids Res. 1989 Feb 11;17(3):1258 [2537954.001]
  • [Cites] J Virol. 1989 Aug;63(8):3307-14 [2545905.001]
  • [Cites] Virology. 1990 Jun;176(2):505-14 [2161148.001]
  • [Cites] Mol Biol Rep. 1990;14(2-3):183-92 [2141907.001]
  • [Cites] J Virol. 1990 Aug;64(8):3905-15 [2164602.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 11;18(21):6456 [2173833.001]
  • [Cites] Biochim Biophys Acta. 1990 Nov 30;1087(3):265-92 [2147394.001]
  • [Cites] Nucleic Acids Res. 1991 May 25;19(10):2785 [1645866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1296-300 [1311093.001]
  • [Cites] Nucleic Acids Res. 1992 Apr 11;20(7):1810 [1315960.001]
  • [Cites] J Cell Biol. 1993 May;121(4):715-27 [8491767.001]
  • [Cites] Cell. 1995 Jan 13;80(1):155-65 [7813012.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3555-65 [8670859.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):265-9 [9207792.001]
  • [Cites] Neurobiol Dis. 1996 Apr;3(2):97-110 [9173917.001]
  • [Cites] Hum Mol Genet. 1997 Aug;6(8):1205-14 [9259265.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1013-21 [9323129.001]
  • [Cites] Cell. 1998 Nov 25;95(5):615-24 [9845364.001]
  • [Cites] Cell. 1999 Feb 5;96(3):375-87 [10025403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11167-72 [10500148.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7540-5 [11748230.001]
  • (PMID = 15632062.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / GEMIN2 protein, human; 0 / Multiprotein Complexes; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Nuclear; 0 / RNA-Binding Proteins; 0 / Recombinant Fusion Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / SMN Complex Proteins
  • [Other-IDs] NLM/ PMC543424
  •  go-up   go-down


58. Lefèvre Y, Ceroni D, Läedermann A, de Rosa V, de Coulon G, Ayse HO, Kaelin A: Pediatric leukemia revealed by a limping episode: a report of four cases. Orthop Traumatol Surg Res; 2009 Feb;95(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric leukemia revealed by a limping episode: a report of four cases.
  • Acute limping in children is a common reason for consultation in pediatric emergency units.
  • Acute leukemia is a rarely encountered disease in the orthopedic surgeon's activity.
  • We report our experience with four cases of children initially seen in the pediatric emergency department for limping, as their revealing presentation of acute leukemia.
  • The physician in charge should remember that paraclinical work-up normal results do not exclude a diagnosis of acute leukemia, that any drop in hematopoietic cell counts should call for a myelogram and that paraclinical exams, including the hemogram, should be repeated until a diagnosis and improvement or confirmed cure is achieved over time.
  • [MeSH-major] Mobility Limitation. Pain / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251241.001).
  • [ISSN] 1877-0568
  • [Journal-full-title] Orthopaedics & traumatology, surgery & research : OTSR
  • [ISO-abbreviation] Orthop Traumatol Surg Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [General-notes] NLM/ Original DateCompleted: 20090708
  •  go-up   go-down


59. Sirulnik LA, Stone RM: Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol; 2005 May;3(5):391-7, 429
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.
  • Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that comprises about 10% of cases.
  • Current treatment strategies with ATRA and anthracycline-based chemotherapy has dramatically transformed APL into the most curable of all acute leukemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167012.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 69
  •  go-up   go-down


60. Bow EJ: Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol; 2009 Jul;46(3):259-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes.
  • Recrudescent neutropenic fevers, defined by the appearance of a new fever after defervescence of the first fever, are often a function of invasive fungal infection or gram-positive infections outside the spectrum of the initial empirical antibacterial regimen.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fever / etiology. Leukemia / drug therapy. Myelodysplastic Syndromes / drug therapy. Neutropenia / etiology


61. Bacigalupo A, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, Ibatici A, di Grazia C, Dominietto A, Piaggio G, Podesta M, Bruno B, Lombardi A, Frassoni F, Viscoli C, Sacchi N, Van Lint MT: Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome. Bone Marrow Transplant; 2007 Mar;39(6):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome.
  • We assessed the long-term outcome of patients with relapsed acute myeloid (n=86) or acute lymphoid leukemia (n=66), undergoing an allogeneic hemopoietic stem cell transplantation in our unit.
  • The median blast count in the marrow was 30%.
  • The donor was a matched donor (n=132) or a family mismatched donor (n=20).
  • Twenty-two patients (15%) survive disease free, with a median follow-up of 14 years: 18 are off medications.
  • In multivariate analysis of survival, favorable predictors were chronic graft-versus-host disease (GvHD) (P=0.0003), donor other than family mismatched (P=0.02), donor age less than 34 years (P=0.02) and blast count less than 30% (P=0.07).
  • This study confirms that a fraction of relapsed leukemias is cured with an allogeneic transplant: selection of patients with a blast count <30%, identification of young, human leukocyte antigen-matched donors and the use of total body radiation may significantly improve the outcome.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Examination. Child. Female. Follow-Up Studies. Graft Survival. Graft vs Host Disease. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Patient Selection. Prognosis. Survivors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277788.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. Li Y, Dai Y, Wu SL, Pei P, Cao XH, Pu DF: [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):588-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia].
  • OBJECTIVE: To explore the relationship between the polymorphism of C46359T in DNMT3B promoter and the pathogenesis of acute leukemia (AL).
  • Compared with TT homozygote, CT heterozygote had a 4.669-fold increased risk of acute leukemia (OR = 4.669; 95% confidence interval 1.700-14.747).
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genotype. Humans. Male. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194411.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


63. Fernandes TA, Fukai R, Souza CA, Lorand-Metze I, Magna LA, Kraemer MH: Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. Blood Cells Mol Dis; 2010 Mar-Apr;44(2):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias.
  • We analyzed a group of 45 Brazilian individuals, 30 with acute myeloid leukemia (AML), 15 with acute lymphoid leukemia (ALL) and 100 healthy controls to assess genetic factor risk and HLA association contribution to the disease.
  • We observed significantly increased allelic distribution of HLA-DRB107 in AML patients and of HLA-DRB103 in ALL patients, which suggests that individuals in both groups are susceptible to the disease.
  • We also found significantly decreased allelic distribution of HLA-DQB104 in AML patients and of HLA-DRB104 and -DQB103 in ALL patients, which suggests protection against the disease.
  • We further found increased HLA-DRB107 and -DQB102 haplotypes in AML patients, which suggests susceptibility to the disease and decreased HLA-DRB104 and -DQB103 haplotypes in ALL patients, which also suggests protection against the disease.
  • Future studies with larger and/or multicentric samples will be required for better comprehension of the HLA role in acute leukemia pathogenesis.
  • [MeSH-major] HLA-DQ Antigens. HLA-DR Antigens. Leukemia, Lymphoid / diagnosis. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Brazil. Female. Follow-Up Studies. Gene Frequency. Genetic Predisposition to Disease. HLA-DQ beta-Chains. HLA-DRB1 Chains. Haplotypes. Humans. Male. Sex Factors

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20051322.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DQ Antigens; 0 / HLA-DQ beta-Chains; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains
  •  go-up   go-down


64. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E, Sugiyama H: Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia; 2005 Aug;19(8):1318-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor Wilms' tumour gene 1 (WT1) is important as a prognostic marker as well as in the detection and monitoring of minimal residual disease in leukaemia and myelodysplastic syndromes.
  • Evidence has accumulated over the past decade to show that WT1 is a key molecule for tumour proliferation in a large number of human neoplasms most prominent in acute leukaemias, making it a suitable target for therapeutic strategies.
  • Based on animal results, showing safety and efficacy of immunization with WT1 peptides and protein, early clinical trials in leukaemia have recently been initiated.
  • [MeSH-minor] Animals. Genes, Wilms Tumor. Humans. Immunotherapy. Leukemia / diagnosis. Leukemia / etiology. Leukemia / therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1318--1323.
  • (PMID = 15920488.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


65. de Greef GE, van Putten WL, Boogaerts M, Huijgens PC, Verdonck LF, Vellenga E, Theobald M, Jacky E, Löwenberg B, Dutch-Belgian Hemato-Oncology Co-operative Group HOVON, Swiss Group for Clinical Cancer Research SAKK: Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol; 2005 Jan;128(2):184-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
  • Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies.
  • This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols.
  • This was independent of blast cells present in the peripheral blood or bone marrow (BM) cellularity.
  • In the same patient group, the presence of extramedullary leukaemia, incomplete platelet (<100 x 10(9)/l) or neutrophil (<1.0 x 10(9)/l) recovery caused a reduced OS and increased RR.
  • In conclusion, < or =5% blasts in the BM, recovery of neutrophils and platelets, and the absence of extramedullary disease constitute the cornerstones for the definition of a haematological CR in patients with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Disease-Free Survival. Female. Humans. Lymphocyte Count. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Risk

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 Apr;129(1):157-8; author reply 158 [15801968.001]
  • (PMID = 15638852.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


66. Staratschek-Jox A, Classen S, Gaarz A, Debey-Pascher S, Schultze JL: Blood-based transcriptomics: leukemias and beyond. Expert Rev Mol Diagn; 2009 Apr;9(3):271-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood-based transcriptomics: leukemias and beyond.
  • In 1999, Golub et al. proposed for the first time microarray-based transcriptional profiling to be used as a new technology for the differential diagnosis of acute myeloid leukemias and acute lymphocytic leukemias.
  • This very preliminary study sparked great enthusiasm beyond the leukemias.
  • Here we highlight the advances in the field of blood transcriptomics during the last 10 years and also critically discuss the issues that need to be resolved before blood transcriptomics will become part of daily diagnostics in the leukemias, as well as in other diseases showing involvement of peripheral blood.
  • [MeSH-major] Blood. Gene Expression Profiling / methods. Leukemia / diagnosis. Leukemia / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Autoimmune Diseases / diagnosis. Autoimmune Diseases / genetics. Humans

  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379085.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


67. Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A: Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol; 2009 Feb;2(1):41-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major causes of morbidity and mortality are represented by arterial and venous thrombosis, as well as by evolution to myelofibrosis or transformation to acute leukemia.
  • However, results of clinical trials with interferon, and the expected effects of novel drugs selectively targeting the abnormal pathways that are involved in the clonal myeloproliferation, are pushing therapeutic goals from disease control only to cure.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082994.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


68. Hmidi K, Zaouali S, Messaoud R, Mahjoub B, Ammari W, Bacha L, Laatiri A, Jenzeri S, Khairallah M: Bilateral orbital myeloid sarcoma as initial manifestation of acute myeloid leukemia. Int Ophthalmol; 2007 Dec;27(6):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral orbital myeloid sarcoma as initial manifestation of acute myeloid leukemia.
  • BACKGROUND: Granulocytic sarcoma is a rare orbital complication of acute leukemia.
  • It concerns primarily children under 10 years of age suffering from primitive acute myeloid leukemia.
  • The diagnosis is made by clinical examination, computed tomography and confirmed by haematological investigations.
  • CASE REPORT: We report the case of a 6-year-old girl who presented with bilateral proptosis revealing acute myeloid leukemia.
  • CONCLUSION: The diagnosis of granulocytic sarcoma should be considered in any orbital mass of uncertain origin, particularly if it is bilateral.
  • Special stains and immunohistochemistry play an important role in the diagnosis.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Orbital Neoplasms / etiology. Sarcoma, Myeloid / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1971 Dec;55(12):844-7 [5290915.001]
  • [Cites] Arch Dis Child. 1981 Jul;56(7):549-51 [7271290.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):466-75 [9053467.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Arch Ophthalmol. 1990 Apr;108(4):484 [2322149.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1993 Nov-Dec;30(6):386-7 [8120745.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):948-50 [15126169.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):255-8 [1902022.001]
  • [Cites] Can J Ophthalmol. 1975 Apr;10(2):174-83 [1055015.001]
  • [Cites] Ophthalmology. 1986 Mar;93(3):379-84 [3703507.001]
  • [Cites] Br J Ophthalmol. 1960 Jul;44:440-2 [13809445.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1101-5 [3460684.001]
  • [Cites] Arch Ophthalmol. 2003 Jan;121(1):138-42 [12523908.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Dec;19(8):597-600 [12487837.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Radiology. 1985 Apr;155(1):167-70 [3856292.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1283-7 [9179903.001]
  • [Cites] Ophthalmologica. 1998;212(3):202-5 [9562099.001]
  • [Cites] Ophthalmology. 1983 Aug;90(8):899-905 [6195573.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):144-9 [9722895.001]
  • [Cites] J Fr Ophtalmol. 2004 Feb;27(2):184-7 [15029050.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2005 Jun;25(3):195-9 [16450777.001]
  • [Cites] Am J Ophthalmol. 1979 Apr;87(4):530-2 [286549.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • [Cites] Arch Ophthalmol. 1991 May;109 (5):734-5 [2025176.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):1-13 [9260575.001]
  • [Cites] Br J Haematol. 1996 Mar;92(4):855-65 [8616078.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Nov;69(11):1595-8 [15939484.001]
  • (PMID = 17522781.001).
  • [ISSN] 0165-5701
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


69. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG: Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol; 2007 Sep 20;25(27):4262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
  • PURPOSE: Hematopoietic stem cell transplantation (HSCT) is an important option in the management of acute leukemia, but the risk of disease relapse and death remains appreciable.
  • Recent studies have suggested that nucleotide-binding oligomerization domain 2 (NOD2)/caspase recruitment domain 15 (CARD15) gene single nucleotide polymorphisms (SNPs), implicated in innate immunity and Crohn's disease, may also affect immune function post-HSCT.
  • PATIENTS AND METHODS: NOD2/CARD15 genotypes were analyzed in 196 patients diagnosed with acute leukemia and their unrelated donors.
  • The pairs are part of a previously well-characterized cohort with a median follow-up of 2.2 years (range, 0.42 to 6.61 years).
  • T-cell depletion was used in 83% of pairs.
  • RESULTS: NOD2/CARD15 SNPs were associated with a reduction in overall survival (44% v 22%; log-rank P = .0087) due to an increase in disease relapse (32% v 54%; Gray's test P = .001) as compared with wild-type pairs.
  • The incidence of acute graft-versus-host disease was low and there was no significant difference due to the presence of SNPs.
  • CONCLUSION: These data indicate an unrecognized role for the NOD2/CARD15 gene in unrelated donor HSCT for acute leukemia.
  • The increased risk of disease relapse suggests that the wild-type gene product may contribute to a graft-versus-leukemia effect.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nod2 Signaling Adaptor Protein / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. HLA Antigens / metabolism. Hematopoietic Stem Cell Transplantation. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 10;26(2):338-9; author reply 339 [18182678.001]
  • (PMID = 17724347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0200231
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  •  go-up   go-down


70. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood; 2008 Jan 15;111(2):566-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
  • Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL).
  • We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia.
  • Patients with APL (n=13) received 0.15 mg/kg per day, and patients with other types of leukemia received 0.15 mg/kg per day (n=2) or 0.2 mg/kg per day (n=4).
  • Non-dose-limiting toxicities included elevated serum transaminases, nausea, vomiting, abdominal pain, constipation, electrolyte imbalance, hyperglycemia, dermatitis, and headache.
  • Morphologic complete response (CR) was achieved in 85% of patients with APL; no responses were observed in non-APL patients.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Lymphoma / drug therapy. Oxides / pharmacokinetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2620-5 [10893295.001]
  • [Cites] Blood. 2001 Jul 15;98(2):266-71 [11435292.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Nov;58(8):521-6 [12451429.001]
  • [Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):165-83 [12635825.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31998-2004 [12767976.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83 [15070760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]
  • [Cites] Clin Chem. 1992 Dec;38(12):2479-83 [1458588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3053-8 [10397243.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • (PMID = 17959855.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00020111
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / UM1 CA097452; United States / NCI NIH HHS / CA / CA97452; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2200837
  •  go-up   go-down


71. Kahng J, Shin SY, Han K: [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation]. Korean J Lab Med; 2007 Dec;27(6):406-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
  • We attempted to discover the proportions of undifferentiated stem cells, committed stem cells, B cell precursors, and myeloid precursors in the regenerating bone marrows during complete remission (CR) and after engraftment of BMT.
  • METHODS: Bone marrow samples from 82 patients with acute leukemia in CR and from 25 patients after BMT engraftment, along with 22 control samples, were used to find the numbers of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells in the large lymphocyte gate by flow cytometry.
  • We cross-analyzed our results in terms of groups: CR, BMT, and initial diagnosis groups.
  • RESULTS: The proportions of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells are more highly distributed in acute B-lymphoblastic leukemia than the normal group and also in the CR than the BMT group.
  • CD19+/CD34+ cells were increased in the relapse group and CD38+/ CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells were increased in the group with chromosomal abnormality.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Bone Marrow Transplantation. Leukemia / metabolism
  • [MeSH-minor] Acute Disease. Bone Marrow / physiology. Flow Cytometry. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / metabolism. Humans. Immunophenotyping. Regeneration. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160830.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


72. Ansari M, Krajinovic M: Pharmacogenomics of acute leukemia. Pharmacogenomics; 2007 Jul;8(7):817-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute leukemia.
  • Leukemia exists in two different forms, myeloid and lymphoid.
  • Acute lymphoblastic leukemia more frequently occurs in children, whereas the risk of acute myeloid leukemia is more common in adults.
  • Prognosis is particularly poor in adult acute myeloid leukemia.
  • Treatment failure in childhood acute lymphoblastic leukemia due to drug resistance remains the leading cause of cancer-related death in children.
  • Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Pharmacogenetics
  • [MeSH-minor] Child. Humans. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240908.001).
  • [ISSN] 1744-8042
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 130
  •  go-up   go-down


73. Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Aurén J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT: Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol; 2008 Mar;80(3):201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
  • OBJECTIVES: Wilms tumour gene 1 (WT1) is overexpressed in leucocytes of most acute myeloid leukaemia (AML) patients.
  • However, the clinical relevance of WT1 gene expression as minimal residual disease (MRD) marker in AML has been questioned.
  • METHODS: We determined the expression of WT1 gene in bone marrow (BM) mononuclear cells of 100 AML patients at diagnosis and compared it with other MRD markers during follow up in 16 patients using quantitative reverse transcription-polymerase chain reaction.
  • RESULTS: The median WT1 gene expression was 9.7% of K562 cell line WT1 expression (lower quartile 1.5%, upper quartile 29.9%, n = 100) at diagnosis and, 0.053% (lower quartile 0.022%, upper quartile 0.125%, n = 87) in molecular or immunophenotypic remission.
  • The upper 99% percentile of remission samples was 0.3%, which was regarded as the cut-off of increased WT1 gene expression in AML and was exceeded in 87% of all AML patients at diagnosis.
  • WT1 expression at diagnosis with median value 9.7% as the cut-off level or as a continuous variable had no prognostic significance for 2-yr survival.
  • [MeSH-major] Bone Marrow Cells / metabolism. Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Confidence Intervals. Disease-Free Survival. Female. Genetic Markers. Humans. Infant. K562 Cells. Male. Middle Aged. Predictive Value of Tests. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081724.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


74. Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, Buck J, Malfroy M, Murphy MF, Williamson LM: The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfus Med; 2009 Dec;19(6):315-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study provides data on National Blood Service (NBS) red blood cell (RBC, n = 9142), platelet (PLT, n = 4232) and fresh frozen plasma (FFP, n = 3584) recipients independently sampled by monthly quota from 29 representative hospitals over 12 months in 2001-2002.
  • The main E-CMGs were digestive [19% of RBC recipients; including 5% gastrointestinal (GI) bleeds and 3% colorectal surgery], musculoskeletal (15%; 12% hip and knee replacement), haematology (13%) and obstetrics and gynaecology (10%).
  • FFP recipients: the main E-CMGs were digestive (21% of FFP recipients; including 7% GI bleeds and 3% colorectal surgery), hepatobiliary (15%; 7% liver disease and 2% liver transplant), cardiac (12%) and paediatrics (9%) The renal, paediatrics, vascular and haematology E-CMGs each had 6-7% of recipients.
  • PLT recipients: the main E-CMGs were haematology (27% of PLT recipients; including 9% lymphoma and 8% acute leukaemia), cardiac (17%), paediatrics (13%), hepatobiliary (10%) and digestive (9%).

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735383.001).
  • [ISSN] 1365-3148
  • [Journal-full-title] Transfusion medicine (Oxford, England)
  • [ISO-abbreviation] Transfus Med
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122870183
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


75. Ringhoffer M, Blumstein N, Neumaier B, Glatting G, von Harsdorf S, Buchmann I, Wiesneth M, Kotzerke J, Zenz T, Buck AK, Schauwecker P, Stilgenbauer S, Döhner H, Reske SN, Bunjes D: 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol; 2005 Aug;130(4):604-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
  • In a phase I-II study for patients aged 55-65 years, we employed radioimmunotherapy using an anti-CD-66 antibody as part of a dose-reduced conditioning regimen, which was followed by a T-cell-depleted graft.
  • 20 patients with a median age of 63 years suffering from acute leukaemia (n=17) or myelodysplastic syndrome (n=3) received the antibody labelled either with 188Rhenium (n=8) or with 90Yttrium (n=12) during conditioning.
  • All patients engrafted, grade II-IV acute graft-versus-host disease (GvHD) was observed in one patient (5%) and chronic GvHD in three patients (15%).
  • The cumulative incidence of non-relapse mortality was 25%, the cumulative incidence of relapse 55%.
  • [MeSH-minor] Aged. Antilymphocyte Serum / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Adhesion Molecules. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Leukemia / radiotherapy. Leukemia / surgery. Leukemia / therapy. Lymphocyte Depletion. Male. Melphalan / therapeutic use. Middle Aged. Myelodysplastic Syndromes / radiotherapy. Myelodysplastic Syndromes / surgery. Myelodysplastic Syndromes / therapy. Radiometry. Rhenium / therapeutic use. Stem Cell Transplantation. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098076.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Immunosuppressive Agents; 0 / Radioisotopes; 0 / Yttrium Radioisotopes; 7440-15-5 / Rhenium; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


76. Yegin ZA, Ozkurt ZN, Aki SZ, Sucak GT: Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transfus Apher Sci; 2010 Jun;42(3):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.
  • Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT).
  • A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD).
  • Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20385512.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Osuji N, Matutes E, Morilla A, Del Giudice I, Wotherspoon A, Catovsky D: Prolonged treatment response in aggressive natural killer cell leukemia. Leuk Lymphoma; 2005 May;46(5):757-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged treatment response in aggressive natural killer cell leukemia.
  • We describe a case of natural killer (NK) cell leukemia with acute presentation, systemic symptoms and hepatosplenomegaly.
  • The uniform and aberrant phenotype of NK cells with infiltration of bone marrow and spleen was in keeping with a malignant diagnosis.
  • We discuss the difficulties in the diagnosis of this condition, explore possible causes of cytopenia(s), and highlight the role of immunosuppression in controlling disease manifestations in large granular lymphocyte proliferative disorders.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural / pathology. Leukemia / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019515.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 395575MZO7 / Pentostatin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


78. Buyukavci M, Olgun H, Ceviz N: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol; 2005 Apr;28(2):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
  • 5-HT3 receptor antagonists, including granisetron and ondansetron, are widely used in the prophylactic treatment of chemotherapy-induced nausea and vomiting.
  • The effects of intravenously infused (over 30 seconds) 0.1 mg/kg ondansetron and 40 microg/kg granisetron on ECG were assessed in 22 children receiving high-dose methotrexate therapy for acute lymphoblastic leukemia.
  • [MeSH-major] Antiemetics / pharmacology. Granisetron / pharmacology. Heart Rate / drug effects. Ondansetron / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Serotonin Antagonists / pharmacology

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2005 Dec;28(6):634-5 [16317278.001]
  • (PMID = 15803017.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antimetabolites, Antineoplastic; 0 / Serotonin Antagonists; 4AF302ESOS / Ondansetron; WZG3J2MCOL / Granisetron; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Kuliszkiewicz-Janus M, Tuz MA, Baczyński S: Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. Biochim Biophys Acta; 2005 Oct 15;1737(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia.
  • The aim of the experiment was to evaluate the changes of phospholipid concentrations in patients (n=30) with acute leukemia compared with reference group of healthy volunteers (n=21).
  • PLs of patients were assayed at least twice: at the time of diagnosis and, when appropriate, at the time of complete remission from the disease (CR).
  • At the time of diagnosis, the mean concentrations of studied compounds were: (1.602+/-0.716) mmol/l for PC+CPLAS; (0.041+/-0.048) mmol/l for LPC; (0.398+/-0.198) mmol/l for SM; (0.045+/-0.071) mmol/l for PI+PE.
  • All concentrations found in patients at the time of diagnosis were significantly lower than in reference group and in those benefited from complete remission (CR).
  • [MeSH-major] Leukemia / blood. Phospholipids / blood
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Phosphorus Isotopes


80. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jäger U, Valent P: Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest; 2009 Oct;39(10):914-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in myeloid leukaemias.
  • MATERIALS AND METHODS: We have determined serum tryptase levels in 914 patients with haematological malignancies, including myeloproliferative disorders (n = 156), myelodysplastic syndromes (MDS, n = 241), acute myeloid leukaemia (AML, n = 317), systemic mastocytosis (SM, n = 81), non-Hodgkin's lymphoma (n = 59) and acute lymphoblastic leukaemia (n = 26).
  • Moreover, tryptase was measured in 136 patients with non-neoplastic haematological disorders, 102 with non-haematological disorders and 164 healthy subjects.
  • The highest tryptase levels, often > 1000 ng mL(-1), were found in advanced SM and core-binding-factor leukaemias.
  • In most patients with non-neoplastic haematological disorders and non-haematological disorders analysed in our study, tryptase levels were normal, the exception being a few patients with end-stage kidney disease and helminth infections, in whom a slightly elevated tryptase was found.
  • [MeSH-major] Leukemia, Myeloid / metabolism. Mast Cells / metabolism. Myelodysplastic Syndromes / metabolism. Myeloproliferative Disorders / metabolism

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522836.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


81. Barber LM, Barlow RA, Meyer S, White DJ, Will AM, Eden TO, Taylor GM: Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia. Br J Haematol; 2005 Sep;130(5):796-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia.
  • [MeSH-major] Alternative Splicing. Fanconi Anemia / genetics. Genes, BRCA2. Leukemia, Myeloid / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Disease Susceptibility. Exons. Fanconi Anemia Complementation Group D2 Protein. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 May;133(4):446-8; author reply 448 [16643458.001]
  • [ErratumIn] Br J Haematol. 2005 Dec;131(5):672
  • (PMID = 16115142.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; 0 / Nuclear Proteins
  •  go-up   go-down


82. Abdulsalam AH: Chemotherapeutic trial for acute leukemia in Iraq. Turk J Haematol; 2009 Dec 5;26(4):216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic trial for acute leukemia in Iraq.
  • [Transliterated title] Irak'ta akut lösemi için kemoterapötik deneme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265640.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


83. Protas PT, Muszynska-Roslan K, Holownia A, Grabowska A, Krawczuk-Rybak M, Braszko JJ: Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning. Neuropediatrics; 2009 Dec;40(6):295-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning.
  • The aim of this study was to ascertain whether changes in the concentrations of cerebrospinal fluid excitatory amino acids (EAAs) contribute to neurotoxicity of the standard acute lymphoblastic leukaemia (ALL) treatment protocols.
  • Cognitive functioning was examined in all patients at an average of 3.7 years after the disease diagnosis.
  • [MeSH-major] Cognition / physiology. Excitatory Amino Acids / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20446226.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Excitatory Amino Acids
  •  go-up   go-down


84. Scolnik MP, Aranguren PN, Cuello MT, Palacios MF, Sanjurjo J, Giunta M, Bracco MM, Acevedo S: Biphenotypic acute leukemia with t(15;17). Leuk Lymphoma; 2005 Apr;46(4):607-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphenotypic acute leukemia with t(15;17).
  • Biphenotypic acute leukemias (BAL) represent 5% of all acute leukemias.
  • Here we report a BAL case, with blasts showing lymphoblast morphology and positivity for myeloperoxidase (in 6% of the blast cells).
  • This report describes a BAL case with an unfrequent cytogenetic abnormality, and highlights the importance of correlating the results of multiple diagnostic methods in order to establish a correct diagnosis and treatment in BAL patients.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Child. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Female. Flow Cytometry / methods. Gene Rearrangement. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence / methods. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trisomy

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019491.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT: Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):60-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
  • However, the role of RASSF1A, SHP-1 and SOCS-1, negative regulators of RTK/RAS signalling, has not been extensively investigated in the myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML).
  • Patients with MDS (n = 107), AML (n = 154) and juvenile myelomonocytic leukaemia (JMML, n = 5) were investigated, together with 15 normal controls.
  • [MeSH-minor] Acute Disease. DNA, Neoplasm / genetics. Humans. Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Myeloid / genetics. Polymerase Chain Reaction / methods. Protein Tyrosine Phosphatase, Non-Receptor Type 6. Protein Tyrosine Phosphatases / genetics. Repressor Proteins / genetics. Sensitivity and Specificity. Sequence Analysis, DNA / methods. Suppressor of Cytokine Signaling Proteins. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801956.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Repressor Proteins; 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Suppressor Proteins; EC 3.1.3.48 / PTPN6 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


87. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res; 2009 Mar 1;15(5):1698-707
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
  • In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias.
  • EXPERIMENTAL DESIGN: Cell survival was examined in vitro in HL-60 human myeloid leukemia cells and K562 myeloid blast crisis chronic myelogenous leukemia cells, using the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and/or fluorescein diacetate/propidium iodide assays.
  • Cell cycle phase distribution was measured by flow cytometry.
  • Cell cycle analyses revealed that the sequence-dependent interaction of vorinostat and ara-C or etoposide reflected the arrest of cells in G1 or G2 phase during vorinostat treatment and recovery into S phase after removal of vorinostat.
  • CONCLUSIONS: These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Blast Crisis. Cell Survival / drug effects. Cytarabine / administration & dosage. Drug Evaluation, Preclinical. Drug Synergism. Etoposide / administration & dosage. G1 Phase / drug effects. Humans. Hydroxamic Acids / administration & dosage. S Phase / drug effects. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223502.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA106767
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 04079A1RDZ / Cytarabine; 58IFB293JI / vorinostat; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


88. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC: Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer; 2008 Oct;47(10):884-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
  • In addition, less common aberrations (particularly gene fusions) involving JAK2 have been described in acute leukemias.
  • In this report, we identify SSBP2 as a new JAK2 fusion partner in a patient with pre-B cell acute lymphocytic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA-Binding Proteins / genetics. Janus Kinase 2 / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Humans. In Situ Hybridization, Fluorescence. Male. Mutation. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618714.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA066996-11A1
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SSBP2 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


89. Arcese W, Buccisano F, Cerretti R, Picardi A, Rome Transplant Network: Cord blood transplantation in adults with acute myeloid leukaemia. Best Pract Res Clin Haematol; 2010 Jun;23(2):197-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cord blood transplantation in adults with acute myeloid leukaemia.
  • Allogeneic haematopoietic stem cell transplantation represents a potential life-saving procedure for many patients affected by acute myeloid leukaemia.
  • However, in the past its application has been limited by the availability of a HLA matched sibling.
  • To date, an allogeneic transplant from alternative haematopoietic stem cell sources (volunteer unrelated donor, umbilical cord blood, haploidentical family donor) should be considered for all patients with high-risk disease defined by integration of clinical and biological prognosticators.
  • Furthermore, the decreased risk of GVHD, the use of reduced intensity conditionings and the graft of double cord blood units permit to extend cord blood transplant to a higher proportion of adult patients with acute myeloid leukaemia, which is predominantly diagnosed in the elderly age.
  • A multicentric, prospective intention-to-treat study is warranted in order to define which haematopoietic stem cell source represents the best choice for allogeneic transplant in high-risk acute myeloid leukaemia.
  • [MeSH-major] Blood Donors. Cord Blood Stem Cell Transplantation / methods. Histocompatibility. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Age Factors. Female. Graft vs Host Disease / prevention & control. Histocompatibility Testing / methods. Humans. Male. Multicenter Studies as Topic. Risk Factors. Transplantation, Homologous


90. Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Kees UR: Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer; 2006 Dec 4;95(11):1537-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
  • Cell lines are important models for drug resistance in acute lymphoblastic leukaemia (ALL), but are often criticised as being unrepresentative of primary disease.
  • We have characterised a panel of ALL cell lines for growth and drug resistance and compared data with that published for primary patient specimens.
  • In contrast to the convention that cell lines are highly proliferative, those established in our laboratory grow at rates similar to estimates of leukaemic cells in vivo (doubling time 53-442 h).
  • A cell line identified as highly methotrexate resistant (IC50 > 8000-fold higher than other lines) was derived from a patient receiving escalating doses of the drug, indicating in vivo selection of resistance as a cause of relapse.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Line, Tumor / drug effects. Drug Resistance, Neoplasm
  • [MeSH-minor] Cell Proliferation. Child. DNA Fingerprinting. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Feb 1;48(3):589-601 [3335022.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3088-91 [3472651.001]
  • [Cites] Blood. 1989 Jul;74(1):369-73 [2546623.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Jun;46(2):201-8 [2340491.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] Lancet. 1991 Aug 17;338(8764):399-403 [1678081.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8900-4 [1681546.001]
  • [Cites] Br J Haematol. 1992 Feb;80(2):189-93 [1550775.001]
  • [Cites] Leuk Res. 1994 Nov;18(11):805-10 [7967706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):201-8 [7536459.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Blood. 1998 Jul 1;92(1):259-66 [9639525.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 15;55(8):1229-34 [9719477.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1344-8 [9737681.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3569-77 [9808549.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):163-71 [10348147.001]
  • [Cites] Leukemia. 1999 Jun;13(6):835-42 [10360369.001]
  • [Cites] Adv Exp Med Biol. 1999;457:551-5 [10500833.001]
  • [Cites] Stem Cells. 2004;22(6):1111-20 [15536200.001]
  • [Cites] Bull Cancer. 2004 Apr;91(4):E80-9 [15562558.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jan;312(1):144-52 [15365089.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):161-5 [15688078.001]
  • [Cites] Neoplasma. 2005;52(1):74-8 [15739031.001]
  • [Cites] Eur J Cancer. 2005 Jun;41(9):1300-3 [15869873.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1357-63 [16109615.001]
  • [Cites] Leuk Res. 1987;11(5):489-98 [3472019.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):139-50 [10769646.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):629-34 [10886214.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):813-8 [11054062.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):59-63 [11196198.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):233-6 [11252900.001]
  • [Cites] Leukemia. 2001 Jun;15(6):929-35 [11417479.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):329-33 [11839374.001]
  • [Cites] Acta Biochim Pol. 2002;49(1):93-8 [12136961.001]
  • [Cites] Leukemia. 2003 Feb;17(2):416-26 [12592342.001]
  • [Cites] Genomics. 2003 Jun;81(6):543-55 [12782123.001]
  • [Cites] Mol Cancer Ther. 2003 Jul;2(7):671-7 [12883040.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4541-6 [12920041.001]
  • [Cites] Ann Rheum Dis. 2004 Feb;63(2):131-7 [14722200.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 30;320(3):825-32 [15240122.001]
  • [Cites] Cancer Res. 1989 Jun 1;49(11):3015-9 [2720661.001]
  • (PMID = 17117183.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2360743
  •  go-up   go-down


91. Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, Vandenberghe P, Depaepe P, De Wolf-Peeters C: Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma; 2007 Sep;48(9):1745-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?
  • To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003.
  • The clinical presentation and cytogenetic characteristics are largely similar for T-ALL and T-LBL supporting the concept that both represent a spectrum of one single disease.
  • The differences that were found between both neoplasms, in particular in their phenotype and in their expression profile may suggest that most T-ALL derive from a T-cell progenitor of the bone marrow, while thymocytes represent the normal counterpart of T-LBL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786710.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Zou Z, Cao X, Wang Z: [P53 abnormality and clinical prognosis of leukemia patients with complex chromosomal abnormalities]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb;27(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [P53 abnormality and clinical prognosis of leukemia patients with complex chromosomal abnormalities].
  • OBJECTIVE: To investigate the p53 deletion in leukemia patients with complex chromosomal abnormalities (CCA) and the clinical significance.
  • METHODS: The p53 deletion status of 38 leukemia cases with CCA and 24 cases without CCA were analyzed by interphase fluorescence in situ hybridization (I-FISH).
  • The rate of complete remission in 13 cases of acute leukemia with CCA was 15.4%, with median survival time (MST) of 105 days.
  • [MeSH-major] Chromosome Aberrations. Gene Deletion. Leukemia / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140875.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


93. Takeda M, Yamaguchi S, Eguchi K, Kajiume T, Nishimura S, Kobayashi M, Kurisu K: Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report. Neurol Med Chir (Tokyo); 2009 May;49(5):221-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report.
  • A 13-year-old boy presented with an epidural thoracic granulocytic sarcoma manifesting as rapidly progressive paraplegia preceding clinical manifestation of acute myeloid leukemia (AML).
  • The initial histological diagnosis was malignant lymphoma.
  • The correct diagnosis of epidural granulocytic sarcoma and AML was established based on cell-surface markers and a chromosomal study of the bone marrow cells.
  • A combination of chemotherapy and bone marrow transfusion achieved complete remission of leukemia.
  • Granulocytic sarcoma should be considered in the differential diagnosis of an epidural mass in pediatric patients with or without acute leukemia.
  • Immediate diagnosis and appropriate treatment are recommended to prevent leukemic transformation.
  • [MeSH-major] Epidural Neoplasms / surgery. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / surgery. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465795.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


94. Larson RA, Le Beau MM: Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact; 2005 May 30;153-154:187-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
  • Therapy-related myeloid leukemia (t-AML) is a distinctive clinical syndrome occurring after exposure to chemotherapy (CT) or radiotherapy (RT).
  • Since 1972, 141 males and 165 females with a median age of 51 years (range: 3-83 years) at primary diagnosis and 58 years (range: 6-86 years) at secondary diagnosis were analyzed.
  • Patients had received various cytotoxic agents including alkylating agents (240 patients, 78%) and topoisomerase II inhibitors (115 patients, 39%).
  • At diagnosis of t-AML, 282 (92%) had clonal abnormalities involving chromosome 5 (n=63), chromosome 7 (n=85), both chromosomes 5 and 7 (n=66), recurring balanced rearrangements (n=31), or other clonal abnormalities (n=39); 24 had a normal karyotype.
  • Seventeen patients had developed t-AML after autologous stem cell transplantation, but no unique pattern of cytogenetic abnormalities was observed.
  • Patients presenting with acute leukemia were more likely to have a balanced rearrangement than those presenting with myelodysplasia (28% versus 4%, p<0.0001).
  • Median survival after diagnosis of t-AML was 8 months; survival at 5 years was less than 10%.
  • To gain insights into the molecular basis of this disease, we performed gene expression profiling of CD34+ hematopoietic progenitor cells from t-AML patients.
  • Leukemias with a -5/del(5q) have a higher expression of genes involved in cell cycle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1), or growth (MYC), and loss of expression of the gene encoding interferon consensus sequence-binding protein (ICSBP).
  • A second subgroup of t-AML is characterized by down-regulation of transcription factors involved in early hematopoiesis (TAL1, GATA1, and EKLF) and overexpression of proteins involved in signaling pathways in myeloid cells (FLT3) and cell survival (BCL2).
  • [MeSH-major] Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 7. Leukemia, Myeloid / genetics. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / genetics. Child. Child, Preschool. Chromosome Aberrations. Female. Gene Expression Profiling. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells. Humans. Male. Middle Aged. Neoplasms / drug therapy. Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15935816.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14599; United States / NCI NIH HHS / CA / CA40046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


95. Koskenvuo M, Möttönen M, Rahiala J, Saarinen-Pihkala UM, Riikonen P, Waris M, Ziegler T, Uhari M, Ruuskanen O, Salmi TT: Mixed bacterial-viral infections in septic children with leukemia. Pediatr Infect Dis J; 2007 Dec;26(12):1133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed bacterial-viral infections in septic children with leukemia.
  • BACKGROUND: Febrile infections in children with leukemia are common.
  • The prospective multicenter survey included 156 febrile episodes in 51 children with acute leukemia.
  • CONCLUSIONS: Our findings suggest that invasive bacterial infections are commonly associated with viral infections in children with leukemia.
  • [MeSH-major] Bacteremia / complications. Leukemia / complications. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043451.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Yu F, Li CW, Wei H, Liu XP, Lin D, Gong JY, Qin S, Xu FY, Mi YC, Wang JX: [Identification of complex chromosomal aberrations in acute leukemia by using conventional cytogenetics combined with multiplex fluorescence in situ hybridization]. Zhonghua Xue Ye Xue Za Zhi; 2010 May;31(5):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of complex chromosomal aberrations in acute leukemia by using conventional cytogenetics combined with multiplex fluorescence in situ hybridization].
  • OBJECTIVE: To explore the value of multiplex fluorescence in situ hybridization (M-FISH) technique in the detection of the complex chromosomal aberrations (CCAs) and marker chromosomes in acute leukemia (AL).
  • The other 29 structural abnormalities including 17 marker chromosomes were characterized by M-FISH.
  • [MeSH-minor] Chromosome Aberrations. Cytogenetics. Humans. Leukemia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122305.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Kriukov AI, Karel'skaia NA: [Therapeutic and diagnostic policy in nasal bleeding in patients with acute leukemia]. Vestn Otorinolaringol; 2007;(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic and diagnostic policy in nasal bleeding in patients with acute leukemia].
  • The algorithm of the otorhinolaryngologist's actions in nasal bleeding (NB) in acute leukemia (AL) patients is presented.
  • [MeSH-major] Algorithms. Aprotinin / therapeutic use. Epistaxis. Fibrinogen / therapeutic use. Health Policy. Leukemia / diagnosis. Leukemia / epidemiology. Thrombin / therapeutic use
  • [MeSH-minor] Acute Disease. Drug Combinations. Humans. Otolaryngology / methods. Tampons, Surgical

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. APROTININ .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495802.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / tachocomb; 9001-32-5 / Fibrinogen; 9087-70-1 / Aprotinin; EC 3.4.21.5 / Thrombin
  • [Number-of-references] 12
  •  go-up   go-down


98. Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, Varotto S, Del Vecchio GC, Dufour C, Ramenghi U, Bacigalupo A, Locasciulli A, Bone Marrow Failure Study Group of the AIEOP (Italian Association of Paediatric Haematology Oncology): Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol; 2008 Jan;140(2):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study, of 42 consecutive children with AAA treated with IST, assessed the incidence of CyA-dependence, CyA and granulocyte colony-stimulating factor (G-CSF) tapering schedules and the impact of drug accumulation on progression to myelodysplasia/acute myeloid leukaemia (MDS/AML).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Drug Administration Schedule. Drug Evaluation. Drug Therapy, Combination. Epidemiologic Methods. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Infant. Male. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173756.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


99. Ogawa K, Noji H, Furukawa M, Harada-Shirado K, Mashimo Y, Takahashi H, Matsumoto H, Kimura S, Shichishima-Nakamura A, Ohkawara H, Ikeda K, Ohto H, Takeishi Y: Hematopoietic stem cell transplantation in the Department of Hematology, Fukushima Medical University. Fukushima J Med Sci; 2010 Dec;56(2):107-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in the Department of Hematology, Fukushima Medical University.
  • From 1996 to the end of 2009, a total of 114 cases of hematopoietic stem cell transplantation were performed in the Department of Hematology, Fukushima Medical University.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed in 37 cases of acute leukemia, 10 of myelodysplastic syndrome, 5 of aplastic anemia, and 5 others.
  • Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 34 cases of malignant lymphoma, 15 of multiple myeloma, and 8 others.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods
  • [MeSH-minor] Academic Medical Centers. Adult. Aged. Female. Humans. Japan. Leukemia / pathology. Lymphoma / pathology. Male. Middle Aged. Myelodysplastic Syndromes / pathology. Prognosis. Research Design. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21502710.001).
  • [ISSN] 2185-4610
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


100. Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK: Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol; 2009 Jun;146(1):54-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party.
  • The role of granulocyte colony stimulating factor (G-CSF) as supportive therapy following intensive induction chemotherapy for acute myeloid leukaemia (AML) in adults was investigated in a randomized trial.
  • Complete remission (CR) rates were similar between arms (73% G-CSF, 75% placebo, P = 0.5), as were reasons for failure (induction death: P = 0.7; resistant disease: P = 0.5) and, for remitters, 5-year disease-free survival (34% vs. 38%, P = 0.3).
  • There is some evidence from this trial of an adverse effect of G-CSF but these data need to be viewed in the context of the evidence from the other trials.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Length of Stay. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Recombinant Proteins / therapeutic use. Remission Induction / methods. Survival Rate. Treatment Outcome. United Kingdom. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438472.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down






Advertisement